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 In today’s world, Alzheimer’s disease (AD) is the leading cause of 
dementia in elderly population across the world. It is also the most common 
neurodegenerative disease. With high prevalence and ever growing incidence 
rate, AD is set to become one of the most crippling diseases in developed and 
developing countries. Currently, only few approved drugs are available for the 
treatment of AD. Majority of them are prescribed to alleviate neuropsychiatric 
symptoms without targeting underlying pathological mechanism. Hence, a lot 
of efforts have been put into the development of disease-modifying drug 
therapy. 
Amyloidogenesis is one of the main culprits of AD pathology. The 
effect of NaHS, a rapid exogenous hydrogen sulfide (H2S) donor, was first 
examined in SH-SY5Y cells transfected with amyloid precursor protein (APP) 
Swedish mutation. H2S pretreatment was found to exert an inhibitory effect on 
Aβ42 synthesis by HENECA (a selective A2A receptor agonist)-stimulated 
SH-SY5Y cells. NaHS also interfered with the maturation process of APP by 
inhibiting its generation and post-translational modification. A further study of 
the rate limiting steps of Aβ synthesis i.e. β- and γ-secretase activities yielded 
interesting results. H2S did not affect the β-secretase activity. However, γ-
secretase activity measurement and gene expression study of presenilins 
revealed that H2S directly inhibited γ-secretase. Curiously, H2S also abrogated 
intracellular cAMP levels and phosphorylation of downstream CREB. H2S had 
similar suppressive effects on cAMP and Aβ42 generation caused by specific 




and gene expression of AC isoforms were preferentially blocked by H2S while 
exerting its inhibitory action on Aβ synthesis. 
 A2A adenosine receptors are known to modulate glutamate uptake in 
astroglial cells. When incubated with HENECA, protein expression of GLAST 
glutamate transporter and glutamate uptake were significantly inhibited in 
astrocytes. The pretreatment with NaHS significantly improved the impaired 
glutamate uptake and expression of GLAST glutamate transporter. Being 
positively linked to AC, stimulation of A2A receptors by HENECA resulted 
into the increase in intracellular cAMP levels.  Similar to the first part of the 
studies, NaHS inhibited the cAMP production in astrocytes. These data 
suggest that H2S -inhibited cAMP production was probably responsible for its 
regenerative effect on glutamate uptake and restoration of GLAST. 
  Several line of evidences show that severe neuroinflammation leads to 
amyloidogenesis in the CNS. By the detailed analysis of generation of many 
inflammatory parameters, it was found that H2S pretreatment suppressed 
extracellular ATP-induced severe neuroinflammation in immortalized BV-2 
cells. While exerting its anti-inflammatory effect, H2S also imparted the 
inhibitory effect on Aβ synthesis in microglia. NF-κB and STAT3 are 
responsible for transcription of many inflammatory genes.  The activation of 
both the transcription factors was blocked by H2S. Cathepsin S, which was 
found to be situated downstream to STAT3 in the current study, was involved 
in β-secretase cleavage of APP and NF-κB activation. We found that H2S s-
sulfhydrated Cathepsin S and inhibited its expression and activity in ATP-




 In conclusion, the present study demonstrated that H2S is a potent 
neuroprotective agent against AD pathology. H2S therapy has a potential to be 
an effective and promising therapeutic strategy against AD as it acts on the 
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1.1 The trio of gasotransmitters  
In recent few decades, the scientific community has witnessed the rise of a 
whole new class of gaseous biological mediators in mammalian cells. The size 
of this family is growing continually over the years since the seminal 
discovery of physiological effects of nitric oxide (NO) on blood vessels 
(Ignarro et al., 1987). With relatively recent recognition of carbon monoxide 
(CO) and hydrogen sulfide (H2S) as two more gaseous signaling molecules, 
the term ‘gasotransmitter’ was coined. As the name suggests, they are simple 
gas molecules, which are lipid soluble and hence freely membrane permeable 
reaching intracellular organelle. In contrast to the conventional idea of typical 
signaling molecules, these gasotransmitters are synthesized endogenously on 
‘as and when required’ basis from specific enzymes in highly regulated 
manner. Many studies over decades studies have revealed that these 
gasotransmitters have specific molecular targets and well defined biological 
functions at physiological concentrations (Wang, 2002b).  
 
1.1.1 H2S- The ‘third’ gasotransmitter 
The physiological role of H2S was discovered by a Japanese group of 
scientists led by Abe and Kimura in 1996. In their pioneering study, the novel 
neuromodulator role of H2S was transpired (Abe and Kimura, 1996). Since 
then its possible roles in all body systems were and are being investigated 
worldwide. In mammalian central nervous system (CNS), its prominent effects 
include modulation of neurotransmission and long-term potentiation (Abe and 




of pathogenic agents. In mammalian cardiovascular system (CVS), its 
protective effects are deeply studied (Polhemus et al., 2014, Liu et al., 2012). 
The induction of relaxation (Yang et al., 2008) and constriction (Kohn et al., 
2012) in various types of blood vessels is also documented (d'Emmanuele di 
Villa Bianca et al., 2011). The opposite effects of H2S on systemic and 
localized inflammation have been observed in various mammalian tissues 
(Whiteman and Winyard, 2011, Hegde and Bhatia, 2011). As more and more 
physiological and pharmacological implications of H2S are explored, we can 
say that its whiff has blossomed (Wang, 2012). 
1.1.1.1 Physical and chemical properties of H2S 
At room temperature and ambient pressure, H2S exists in a colorless 
gaseous form.  The smell is very pungent with distinctive rotten-egg odour. It 
is readily water soluble due to its weak acidic nature. Its solubility was 
measured to be 80 mM at 37 °C as equilibrium between H2S, HS- and S2-. The 
acid dissociation constant (pKa) values of the first and second dissociation 
steps are recorded as 7.0 and >12.0, respectively (Vorobets et al., 2002, Kabil 
and Banerjee, 2010, Mark et al., 2011). Thus, at physiological pH of 7.4, H2S 
exists majorly as HS- moiety along with minor presence of free H2S in its 
dissociated form. The minute amounts of sulfide anions (S2-) can also be 
detected. Even with the advent of various methods of H2S measurement, it’s 
almost impossible to determine the active form of H2S (H2S, HS- or S2-) 
present in the biological system. Hence the all-encompassing term of H2S is 
now used to refer the total sulfide content present in the solution (i.e. H2S + 




1.1.1.2 Toxicity of H2S 
H2S is often a lethal environmental and occupational hazard that has a 
unique pattern of toxicity. It is the second most common cause (at 7.7%, after 
carbon monoxide at 36%) of fatal gas inhalation exposure at the workplaces 
like oil rigs and urban sewers (Guidotti, 2010). Its exposure-response curve for 
lethality is steep, thus concentration of inhaled gas is more important 
compared to the duration of exposure (Prior et al., 1988, Guidotti, 1996). The 
approximate concentrations (exposure levels) of inhaled H2S for the major 
toxicological effects are given in table 1. The toxidrome (i.e. a set of 
symptoms and signs associated with a particular poison) of H2S is often 
considered as one of the most unusual and reliable toxidromes (Milby and 
Baselt, 1999, Wang, 1989). It is characterized by the ‘knockdown’ (acute 
central neurotoxicity), pulmonary edema, conjunctivitis and odor perception 
followed by respiratory paralysis (Guidotti, 2010). Acute toxicity leading to 
reversible unconsciousness caused by H2S inhalation are called as 
‘knockdowns’ (Guidotti, 1996). Although knockdowns can be fatal in the 
cases of prolonged high-concentration exposure of about 500-1000 ppm 
(about 15-30 mM), the transient exposure is often reversible and apparently 
complete functionally (Burnett et al., 1977). Pulmonary edema is a well-
recognized effect of acute H2S toxicity. As H2S has relatively high solubility, 
it penetrates deeply into respiratory track, causing alveolar injury culminating 
in acute pulmonary edema (Guidotti, 2010). The conjunctivitis, caused by 
prolonged low-concentration exposure of about 20 ppm (about 500 uM) 
(Lambert et al., 2006) is peculiarly associated with reversible chromatic 




by blepherospasm and photophobia (Tansy et al., 1981, Milby and Baselt, 
1999). H2S is an odorous gas at low concentration of 0.01-0.3 ppm (about 0.09 
mM). As the concentration increases, however, the victims start to experience 
olfactory fatigue. It is a sensory adaptation where the victims get accustomed 
to strong odor. At around 100 ppm (about 3 mM) concentration, H2S paralyses 
the olfactory mechanism, preventing perception of any smell. This 
phenomenon removes the primary warning sign of H2S exposure (Ronk and 





Minimum concentration detected by human nose (may 
differ from person to person) 
1-5 
Generally tolerated pungent smell, although some 
people can shows symptoms like nausea, mild 
lacrimation and possible heavy-headedness 
10 
Threshold for anaerobic metabolism in normal person 
during exercise 
20 
Strong characteristic odor, probable eye irritation or 
conjunctivitis 
20-50 
Eye and lung irritation, delayed eye damage in few 
victims, appearance of symptoms of gastric 
disturbances 
100 
Eye and lung irritation; olfactory paralysis, 




150-200 Severe eye and lung irritation, sense of smell paralyzed 
250-500 Long term exposure might lead to pulmonary edema 
500 
Serious damage to eyes, severe lung irritation, 
knockdown and death within 4-8 hours, amnesia for 
period of exposure 
1000 Immediate cessation of breathing; instant collapse 
 
Table 1 Health effects of H2S at various approximate exposure levels. Data is reproduced 
from (Guidotti, 1996, Guidotti, 2010) with some modifications. 
1.1.1.3 Biosynthesis of H2S 
In mammalian tissues, H2S is biosynthesized from amino acid cysteine  
(Cys) and homocysteine (Hcy), which are recognized as the principle 
substrates for its endogenous production.  They are acted upon by three 
different enzymes, namely cystathionine β-synthase (CBS), cystathionine γ-
lyase (CSE) and 3-mercaptopyruvate sulfur transferase (3-MST) (Hu et al., 
2011). Expressions of these enzymes are variable in different tissues. The 
study of this variation is important as the modulation of endogenous 
production of H2S can be achieved by targeting each enzyme separately or 
concurrently. 
 A pyridoxal-5’-phosphate (PLP)-dependent enzyme, CBS, initiates the 
trans-sulfuration pathway by catalyzing β-replacement of serine by Hcy to 
generate cystathionine and water. Furthermore, serine replacement by cysteine 
as a substrate results into production of cystathionine and H2S. Besides above 




reactions between two molecules of Cys and β-replacement of Cys by water to 
produces H2S (Kabil and Banerjee, 2014). The reaction replacing Hcy by Cys 
yields maximum generation of H2S in vitro (Singh et al., 2009). CBS is found 
to be primarily expressed in various regions of the human brain (Abe and 
Kimura, 1996). 
 CSE is yet another PLP-dependent enzyme, which mediates a reaction 
between thiocysteine and a thiol compound R-SH to generate H2S (Kimura, 
2011). The substrate thiocysteine is generated from L-cystine which in turn is 
produced by two L-cysteine molecules (Yamanishi and Tuboi, 1981). 
Expression of CSE is rather widely distributed among peripheral tissues 
including liver, pancreas, uterus and intestine (Kimura, 2011). It is the main 
H2S-generating enzyme in the cardiovascular system (Zhao et al., 2001, Bian 
et al., 2006). CSE was detected in relatively large amounts in the myocardium 
(Geng et al., 2004), endothelial cells (ECs) (Yang et al., 2008), and smooth 
muscle cells (Zhao et al., 2001).  
 The third enzyme, 3-mercaptopyruvate sulfotransferase (3-MST), was 
identified in the neurons. The research group detected the significant presence 
of H2S in the brain homogenate preparation of CBS-/- mice (Shibuya et al., 
2009). Kimura further observed that 3-MST acts together with cysteine 
aminotransferase (CAT) to generate H2S from Cys in the presence of α-
ketoglutarate (Kimura et al., 2010). However, it is suggested that 3-MST is 
unable to produce H2S in normal physiological conditions as they exert their 
activities at higher alkaline pH level. Furthermore, it requires endogenous 
reducing substances such as thioredoxin and dihydrolipoic acid (DHLA) for 




CAT, competitively binding to it and attenuating H2S synthesis (Guo et al., 
2012).  
Recently, Shibuya et al discovered the additional pathway for H2S 
biosynthesis in mammalian cells. 3-MST along with D-Amino acid oxidase 
(DAO) produces H2S from D-Cysteine by the interaction of mitochondria and 
peroxisomes. It was evident that this D-Cysteine dependent pathway operates 
predominantly in the cerebellum and the kidney. The protective effects of D-
Cysteine were observed against oxidative stress in cerebellar neurons and 
against ischaemia-reperfusion injury in the kidney (Shibuya and Kimura, 
2013).  
1.1.1.4 Storage and metabolism of H2S  
Although endogenous H2S can be synthesized and released 
immediately, the storage forms of H2S are also known. Acid-labile sulfur is 
primarily contained in iron-sulfur center of mitochondrial enzymes and can 
release H2S only in acidic pH of 5.4. Due to higher instability of iron-sulfur 
complexes, the release of H2S is readily achieved. Bound sulfane sulfur, which 
is localized in cytoplasm, consists of divalent sulfur bond (e.g. persulfide 
form). It releases H2S under reducing conditions of pH 8.4 (Ishigami et al., 
2009). It is possible that H2S produced by 3-MST/CAT enzymatic pathway is 
stored in the bound sulfane sulfur form. The decreased amount of bound 
sulfane sulfur has been detected in cells without 3-MST/CAT compared to the 
cells with it (Shibuya et al., 2009).  
H2S is catabolized in mammalian cells though various pathways. The 




(Hildebrandt and Grieshaber, 2008). In a reaction catalyzed by quinone 
oxidoreductase enzyme, H2S is converted into persulfides. Persulfides are, in 
turn, oxidized in sulfite and thiosulfite. In physiological normoxic conditions, 
the thiosulfite is further metabolized into excretable form of sulfate. H2S 
catabolism by quinone oxidoreductase enzyme seems to be universal in 
mammalian tissues, with possible exception of the brain (Mikami et al., 2011). 
H2S can also be methylated to produce methane thiol by the action of enzyme 
thiol-S-methyltransferase. Non-mitochondrial heme proteins such as 
hemoglobin and myoglobin also catabolize intracellular H2S by oxidation 
(Berzofsky et al., 1971, Stein and Bailey, 2013). To a smaller extent, H2S can 
also interact with reactive oxygen and nitrogen species.  It is interesting to 
know that the presence of oxygen (O2)  is very influential factor in deciding 
the fate of cellular H2S as O2 is capable of spontaneous oxidization of H2S 
(Stein and Bailey, 2013, van Kampen and Zijlstra, 1983). The intracellular 
concentration of H2S is firmly kept in low range, owing to the highly efficient 
nature of above-mentioned mechanisms.  
1.1.1.5 Biological role of H2S in CNS 
1.1.1.5.1 Physiological Roles 
 The protective effects of H2S on various cell types of CNS in various 
in vitro experiments and animal models are being widely investigated. 
Oxidative stress caused by overproduction of reactive oxygen species (ROS) is 
detrimental and one of the etiological factors of many neurodegenerative 
diseases. Kimura et al found that H2S protects primary neurons from oxidative 




glutathione levels by enhancing the activity of gamma-glutamylcysteine 
synthetase and up-regulating cystine transport. The upregulation in gamma-
glutamylcysteine synthetase activity facilitates the redistribution of GSH into 
mitochondria, thus protecting cells against oxidative stress damage (Kimura 
and Kimura, 2004). Later, the same group also discovered that H2S protects 
immortalized mouse hippocampal cells from oxytosis by activating ATP-
dependent K+ (KATP) and Cl- channels, in addition to increasing the levels of 
glutathione (Kimura et al., 2006). A study conducted by Lu et al demonstrated 
that H2S protects astrocytes via enhancing glutamate uptake function of 
glutamate transporter-1 and elevating glutathione (GSH) production. This 
phenomenon prevents excessive accumulation of glutamate in synaptic clefts 
protecting neurons from excitotoxicity (Lu et al., 2008). Besides these, H2S 
downregulates peroxynitrite-mediated tyrosine nitration and inactivation of 
alpha1-antiproteinase inhibiting peroxynitrite-induced cytotoxicity, 
intracellular protein nitration and protein oxidation in human neuroblastoma 
SH-SY5Y cells (Whiteman et al., 2004). Apart from anti-oxidation effects, 
H2S is also known to possess anti-apoptotic properties conferring 
neuroprotection. Hu and colleagues discovered that H2S inhibits apoptosis 
induced by rotenone (a toxin used to establish Parkinson’s disease model) by 
preserving mitochondrial functions in human neuroblastoma cell line (SH-
SY5Y). They observed that H2S regulated the mitoKATP channel and thus 
impeded the apoptosis cascade (prevention of mitochondrial membrane 
potential (MMP) dissipation, cytochrome c release and caspase-9/3 activation) 
(Hu et al., 2009). The anti-apoptotic effect was supported by other studies as 




vascular dementia via inhibiting apoptosis in rats (Zhang et al., 2009). In yet 
another study, H2S imparted the cytoprotective effect to PC12 cells against 
amyloid β (25-35)-induced apoptosis (Tang et al., 2008).  
One of the most important and widely studied roles of H2S is its action 
as neuromodulator by regulating neurotransmission in and between neurons.  
It particularly stimulates N-methyl-D-Aspartate (NMDA) receptor mediated 
currents facilitating the induction of long-term potentiation (LTP) and synaptic 
plasticity. Both phenomena are involved in learning and memory. H2S 
increases NMDA receptor sensitivity to glutamate through activation of 
downstream adenylyl cyclase (AC) and ensuing cAMP/protein kinase A 
(PKA) pathway (Abe and Kimura, 1996). As discussed earlier, H2S facilitates 
clearing of excessive glutamate from synaptic clefts, thus maintaining normal 
inter-neuronal signaling unhampered (Lu et al., 2008).  
The effect of H2S on intracellular calcium [Ca2+]i deserves a special 
mention here. [Ca2+]i is critical for normal neuron-glia communication and 
regulation of synaptic plasticity. It has been found that H2S is capable of 
regulating [Ca2+]i in all important brain cell types; namely neurons (Yong et 
al., 2010), microglia (Lee et al., 2006b)  and astrocytes (Nagai et al., 2004). 
There are two main mechanisms by which [Ca2+]i is elevated in H2S 
stimulated cells; one by its release from intracellular calcium store and other 
by its influx via calcium channels located on plasma membrane. H2S, having 
multi-targeted actions, stimulate different channels and secondary signaling 
pathways. It activates L-/T-type calcium channels and NMDA receptors on 
plasma membrane (Lee et al., 2006b). Yong at al discovered that the action of 




(PLC) and protein kinase C (PKC), suggesting the role of PKA and PLC/PKC 
pathways in the regulatory effect of H2S on [Ca2+]i (Yong et al., 2010). 
Furthermore, in a recent study conducted by Sekiguchi et al demonstrated that 
the function of Cav3.2 T-type Ca2+ channels (T-channels) is tonically 
enhanced by endogenous H2S synthesized by CSE in HEK293 cells 
transfected with Cav3.2 , and that exogenous H2S is capable of enhancing 
Cav3.2 function when endogenous H2S production by CSE is inhibited 
(Sekiguchi et al., 2014). In yet another study done previously by the same 
group suggests the T-type Ca2+ channels are involved in induction of 
neuritogenesis and expression of high-voltage-activated currents in NG108-15 
cells by H2S (Nagasawa et al., 2009).  
1.1.1.5.2 Pathological Roles 
Parkinson’s disease  
Parkinson’s disease (PD) is the second most common 
neurodegenerative disease histopathologically characterized by progressive 
degeneration of dopaminergic neurons in substantia nigra of midbrain.  
Many studies indicate that hyperhomocysteinemia (abnormally high 
level of homocysteine in the blood) is common in the patients of PD 
(O'Suilleabhain et al., 2004, Zoccolella et al., 2010). Various experiments in 
PD animal models detected reduced levels of H2S in substantia nigra and 
striatum regions of the brain. These findings suggest that impaired endogenous 
production of H2S has a substantial effect on pathogenesis and progression of 
PD. Furthermore, the administration of exogenous H2S has shown protective 




Zhau et al demonstrated that NaHS, a fast H2S donor, protected PC12 cells 
from cytotoxicity and apoptosis induced by MPP+, the active metabolite of 
MPTP. They found that H2S inhibited the loss of MMP and the accumulation 
of intracellular ROS (Yin et al., 2009). Recently, Li et al (Xie et al., 2013) 
confirmed the initial findings of Calvert and colleagues (Calvert et al., 2009) 
about upregulation of endogenous antioxidants by H2S via stimulation of 
nuclear-factor-E2–related (Nrf2)-dependent signaling pathway. Previously, it 
was shown that pretreatment with NaHS can protect human neuroblastoma 
SH-SY5Y cells against rotenone-induced apoptosis (Hu et al., 2009) and 6-
OHDA-induced cell injury (Tiong et al., 2010).  
These findings in vitro studies were supported by the observations 
done in animal models of PD. Hu et al found out that the systemic 
administration of NaHS dramatically reversed the progression of movement 
dysfunction, loss of tyrosine-hydroxylase (TH) positive neurons in the 
striatum and the elevated malondialdehyde level in injured striatum caused by 
6-OHDA or rotenone (Hu et al., 2010). Inhaled H2S also prevented the MPTP-
induced movement disorder and the degeneration of TH-containing neurons 
by upregulating heme oxygenase-1 and glutamate-cysteine ligase (Kida et al., 
2011). The anti-inflammatory, antioxidant and neuroprotective properties 
shown by new H2S releasing hybrids are encouraging thus making them ideal 
candidates for PD treatment. ACS 84, a well-known L-DOPA hybrid, has been 
effective in reducing the release of pro-inflammatory cytokines and NO from 
stimulated microglia and astrocytes (Lee et al., 2010). Beside relieving from 




dopamine levels by inhibiting mono-amine oxidase B activity (Sparatore et al., 
2011). 
These findings highlight the potential therapeutic benefit of H2S in PD 
which can be achieved either by the administration of exogenous H2S or the 
modulation of endogenous H2S production. 
Vascular Dementia 
 Vascular dementia (VD), a heterogeneous group of brain disorders in 
which cognitive impairment is attributable to cerebrovascular pathologies, is 
responsible for at least 20% of cases of dementia, being second only to 
Alzheimer’s disease (Gorelick et al., 2011, Iadecola, 2013). A pioneering 
study done by Zhang et al suggests that H2S could protect the brain against 
VD injury induced by cerebral ischemia reperfusion through inhibiting the 
apoptosis in the hippocampus. They found that NaHS-treated rats had a greater 
ratio of Bcl-2 (anti-apoptotic) over Bax (pro-apoptotic) with increased Bcl-2 
expression and decreased Bax expression in the hippocampus (Zhang et al., 
2009). It is generally believed that inflammation (Malaguarnera et al., 2006, 
Liu et al., 2007), oxidative stress (Liu et al., 2007) and vascular factors 
(Brown et al., 2007, Stephan and Brayne, 2008) play important roles in the 
VD pathology. As discussed earlier in this thesis, H2S possesses potent anti-
inflammatory (Hu et al., 2007b) and anti-oxidative action (Kimura and 
Kimura, 2004). It has also been shown that H2S exerts cardioprotective action 
against myocardial ischemia reperfusion injury (Elrod et al., 2007). Hence, it 
appears that H2S may protect against VD injury by targeting multiple 




Ischemic stroke  
 Ischemic stroke often results into loss of brain functions due to the 
neuronal damage in the ischemic area (Mestriner et al., 2013). Hippocampus is 
one of the regions more prone to an ischemic insult (Gordan et al., 2012). 
Hippocampus plays a very important role in memory retention and spatial 
navigation. Thus, damages to this region cause a significant loss in memory 
and learning (Wen et al., 2014).  
 It has been known that exogenous H2S treatment improves myocardial 
dysfunction related to ischemia/reperfusion injury (Lowicka and Beltowski, 
2007). The beneficial effects of H2S were also investigated in CNS models of 
ischemia. An interesting study done on mild focal cerebral ischemia rat model 
showed that H2S at a low concentration remarkably lessened the injury 
(Florian et al., 2008). Kimura et al demonstrated that H2S reinstated 
glutathione (GSH) levels in the fetal brain decreased by ischemia/reperfusion 
in utero (Kimura et al., 2010). While studying the effects of H2S on global 
cerebral ischemia–reperfusion (I/R), Yin and colleagues found out its potent 
protective effect against a severe cerebral injury through the inhibition of 
oxidative stress, inflammation and apoptosis (Yin et al., 2013).  Recently 
Wang et al reported that H2S donors protected blood brain barrier integrity in 
MCAO (middle cerebral artery occlusion) rat model by inhibiting NF-κB and 
suppressing post-ischemic inflammation-induced Matrix Metalloproteimase-9 
(MMP9) and Nicotinamide adenine dinucleotide phosphate oxidase (NOX) 
(Wang et al., 2014). In the same disease model, it was revealed that the H2S 
treatment can promote angiogenesis and thus improve the functional outcome 




team have reported that H2S improved the survival rate of hippocampal 
neurons thus reducing the learning and memory impairment in the rats with 
induced ischemic stroke. H2S increased the phosphorylation of Akt while 
inhibited the phosphorylation of ASK1 and JNK3 (Wen et al., 2014).  
 
1.2 Alzheimer’s disease 
1.2.1 History 
About a century ago, during a lecture at the 37th annual conference of 
German psychiatrists in Tubingen, a German neuropathologist and psychiatrist 
named Dr. Aloysius "Alois" Alzheimer described ‘a particular disease of 
cerebral cortex’ of his patient Mrs. Auguste Deter. The patient had presented 
with the history of impaired memory, cognitive impairment, hallucinations, 
delusion, aphasia, disorientation and psychosocial incompetence. A detailed 
post-mortem analysis of her brain revealed many peculiar findings such as 
atrophied brain and presence of plaques and neurofibrillary tangles. Later, this 
presenile dementia, on suggestion of Dr. Alzheimer’s boss Emil Kraepelin, 
became known as Alzheimer’s disease (AD) (Maurer et al., 1997). As of 
today, AD is the single most common cause of dementia in elderly population 
across the world (Reitz et al., 2011a). AD still has undetermined etiology and 
it’s definitive diagnosis can only be obtained post-mortem. Currently, lots of 






In 2005, 24.2 million people worldwide had dementia.  The developed 
world i.e. north America and western Europe showed the highest prevalence 
of dementia. It is estimated that these parts of the world along with China will 
be home to around 55% of total affected population worldwide by 2040. The 
prevalence of dementia grows with the age. The extensive Delphi consensus 
study done by Ferri et al revealed the growth from 1% in 60-64 years age 
group to about 30% in those of >85 years age group. The incidence rate of AD 
and other dementias also increase exponentially with the age, mirroring the 
prevalence rate. The worst affected is the seventh and eighth decades of life 


















































































2.7 5.9 0.6 325 
India and 
South Asia 
1.9 4.3 1.8 314 
Africa 1.6 3.5 0.5 235 
Combined 
Values 
3.9 7.5 24.3 234 
 
Table 2 Prevalence and incidence of dementia in developed and developing regions Data 
is reproduced from (Ferri et al., 2005) with some modifications. 
	  
1.2.3 Risk factors 
A risk factor is any attribute, characteristic or exposure of an individual 
that increases the likelihood of developing a disease or injury (WHO, 2014). 
Various risk factors have been found to be associated with dementia and AD. 
Recent advances indicate dementia risk is modified by perinatal events, 
education status, nutritional intake, degree of physical activity, and cognitive 
and social engagement. Several of these factors impact adult-onset vascular 
disorders such as stroke, hypertension, atherosclerotic disease, type 2 diabetes 
mellitus, hyperinsulinemia, hyperglycemia, dyslipidemia, 
hyperhomocysteinemia and obesity. It is increasingly recognized that factors 




onset or progression of late-onset dementias and AD (Kalaria, 2010, Reitz et 
al., 2011a).  
 
1.2.4 Pathology 
Classically, AD pathology is characterized by the formation and 
accumulation of misfolded proteins (plaques and tangles) in the brain. 
Amyloid β and tau have been identified as main components of plaques and 
tangles respectively. 
1.2.4.1 Amyloid β 
 The formation of extracellular plaques is described by generally 
accepted amyloid cascade theory. The theory states that extracellular plaques 
are primarily made up of Aβ, which is a 40 to 42 amino acids long peptide and 
is generated by sequential proteolytic cleavage of the larger amyloid precursor 
protein (APP) (Selkoe, 1991). In non-amyloidogenic pathway, APP is cleaved 
within the Aβ domain by α- secretase, releasing soluble APP (sAPPα) 
extracellularly. On the other hand, poorly soluble amyloidogenic Aβ is derived 
from sequential cleavage of APP by β- and γ-secretases (Cummings et al., 
1998).  
About 25 years ago, it was contemplated that certain mutations in APP 
gene would be detected in familial AD (Goate et al., 1989). Since then, 20 
mis-sense mutations have been described in the literature (Goedert and 
Spillantini, 2006). The mutations in APP lead to increased production of Aβ 




mutations don’t account for majority for familial AD cases. The mutations in 
presenilin-1 (PS1) gene have proven to be mainly responsible for familial AD 
(Schellenberg et al., 1992, Sherrington et al., 1995). Mutations in presenilin-2 
gene have also been found to initiate AD pathology (Rogaev et al., 1995). In 
fact, scientists have recognized around 150 mutations in presenilin genes 
(Goedert and Spillantini, 2006). Presenilins form the catalytic subunits of 
high-molecular weight complex of γ-secretase (De Strooper et al., 1998). PS1 
mutations result into reduced γ-secretase activity (Citron et al., 1997) and 
increased proportion of Aβ42 in overall production of Aβ. The pathological 
investigations done in preclinical cases with PS-1 mutations, Aβ42 deposition 
was found out to be an early event (Lippa et al., 1998). It is interesting to 
know that no mutations were detected in BACE1, which is involved in the 
rate-limiting step of β-secretase cleavage of APP in Aβ formation (Vassar et 
al., 1999). Overall, the findings on familial AD support amyloid cascade 
theory, which expounds that elevated Aβ42 levels initiate AD pathology, 
which set up the cascade of downstream events.  
1.2.4.2 Tau 
Another major hallmark of AD related changes in the brain is 
intracellular development of neurofibrillary tangles (NFTs). NFTs are 
primarily made of paired helical filaments (PHF). The main component of the 
NFTs is tau, a microtubule related protein (MAP) (Grundke-Iqbal et al., 1986). 
It provides structural stability to a cell by binding to microtubulin. Tau protein 
accumulation results from its dissociation from the microtublin (Su et al., 
1996). The reason behind  this  aggregation phenomenon is explained by the 




undergoes phosphorylation and dephosphorylation, forming insoluble 
aggregates. Any imbalance results into elevated levels of abnormally 
hyperphoshorylated tau (P-tau 181, P-tau 199, P-tau 231, P-tau 396 and P-tau 
404), which in turn sequesters normal tau and other MAPs (MAP1 and MAP2) 
(Blennow et al., 2007). PHF and tangle formation are direct results of 
aggregation of hyperphosphorylated tau. The microtubules disassembly is 
another process, which runs parallel to the process of tangle formation. Both 
the process result into dysfunctional neuronal and synaptic function (Blennow 
et al., 2006). The amyloid cascade hypothesis states that elevated levels of Aβ 
can trigger the changes in tau protein culminating into formation of NFTs. It 
has been shown that protein α-synuclein (core components of lewy body based 
pathologies, known as synucleinopathies), like tau is involved in microtubule 
assembly. It serves as a binding for the tubulin. Mutations in α-synuclein lead 
to loss of this binding ability, resulting in tubulin and α-synuclein aggregation. 
Properly functioning microtubules are important for normal neuronal and 
synaptic functions. Any alteration in microtubule assembly may be key event 
in neurodegenerative disease (Alim et al., 2004).  
1.2.4.3 Studies done on animal models and AD patients 
 The studies conducted on P301L human tau mutation transgenic mouse 
model have shown the increased production of tangles (Van Dam and De 
Deyn, 2006). It supports the notion of the core symptoms of AD have 
neurobiological basis with the pathological accumulation of amyloid peptide 
and NFTs, often growing independently, and with different distribution pattern 
(Braak et al., 1999, Van Dam and De Deyn, 2006). The topographic 




on post mortem brains of AD patients. The brain regions involved are the 
medial temporal cortex, hippocampus, and entorhinal cortex, anterior 
cingulate gyrus (as well as disruption of the neocortex) - whilst other areas are 
unaffected - prominently cerebral and cerebellar cortex. This distribution or 
topographically predictive nature of aggregation is thought to be a V to VI 
stage process whereby the first three stages are preclinical, with symptomatic 
or clinically diagnosable symptoms becoming prominent from stages III 
onwards. The amnesia occurs due to the affected hippocampus producing 
early memory changes and ultimately the progression to the final stage, where 
the neocortex is affected (Braak and Braak, 1991, Braak et al., 1999). 
Moreover, it has been recently shown that tangle formation is an early event to 
amyloid deposition (Braak and Del Tredici, 2004, Schonheit et al., 2004). This 
is contrast to amyloid cascade theory, which states that amyloid deposition 
leads to tangle formation (Hardy and Higgins, 1992). The novel creation of 
3xTgAD APP Swedish mutation has supported this hypothesis (Oddo et al., 
2003, Van Dam and De Deyn, 2006) showing amyloid deposition, as an event 
preceding tangle formation. Combination of the APP Swedish mutation and 
P301L models have yielded both sets of pathologies; with amyloid considered 
a bit more pathologic in nature, and therefore more likely to cause dementia. 
1.2.4.4 Other etiopathological hypotheses  
Oxidative Stress 
Oxidative stress damages various biomolecules in an unregulated 
manner and is considered to be one of the hallmark pathological features of 
neurodegenerative diseases. It is also believed that the plaques and tangles are 




initiator of the disease pathology. Thus the subsequent emergence of Aβ 
deposits and tau hyperphosphorylation is a consequence of the defense (Smith 
et al., 2002). It has also been shown that oxidative damages precedes other 




Brain regions affected by AD are known to contain elevated mediators 
of neuroinflammation through increased inflammatory cascades (Wyss-Coray 
and Mucke, 2002). Cyclooxygenase (COX), an important mediator of the 
inflammatory cascade is acted upon  by non-steroidal anti-inflammatory drugs 
(NSAIDs),  affecting expression of COXs. There is a plenty of evidence 
showing beneficial effects of NSAIDs in AD pathology. Some effects are 
independent of COX inhibition. NSAIDs can reduce Aβ deposits in animal 
models of AD (Weggen et al., 2001). Microglia activation is thought to be an 
early event in the Alzheimer’s disease pathogenesis and may be critical in 
synaptic disruption and thus early memory impairment (Cagnin et al., 2001). 
The Alzheimer’s disease Anti-inflammatory prevention Trial (ADAPT) 
looked into the role of NSAIDs in people vulnerable to dementia, using COX-
1 and COX-2 drugs. The trial was cancelled due to cardiovascular risks 
(ADAPT, 2006). Overall COX-1 targeting NSAIDs are thought to be a better 
option than COX-2 inhibitors (McGeer and McGeer, 2007). 
 




The cholinergic hypothesis of AD suggests that altered cholinergic 
pathway in the forebrain results into a reduction of cholinergic neurons, which 
in turn results into lowered production of neurotransmitter acetylcholine 
(Bartus, 2000, Terry and Buccafusco, 2003). These neurons project to the 
hippocampus and neocortex, which are implicated in both memory disturbance 
and cognitive symptoms (Bartus, 2000). Enzyme acetylcholinesterase (AChE) 
degrades ACh. Lowered levels of AChE were observed in moderate to severe 
AD patients. The inhibition of AChE improves neurotransmitter function and 
provides symptomatic relief to AD  patients (Terry and Buccafusco, 2003).  
 
Cholesterol hypothesis of AD 
The definitive role of cholesterol metabolism in AD pathogenesis is 
gaining acceptability (Puglielli et al., 2003). Cholesterol affects the enzyme 
activities involved in APP metabolism during the production of Aβ. Statins, 
cholesterol-lowering drugs have been shown to lower the risk of developing 
dementia (McGuinness et al., 2014). Apolipoprotein E (APOE) is involved in 
the transporting of cholesterol, and APOE ε4 allele is a universally accepted 
marker which enhances AD risk (Corder et al., 1993). APOE ε4 is also 
associated with lowering the age of onset for AD (McGuinness et al., 2014). 
APOE ε4 not only confers a genetic risk for AD, it is also associated with the 
production and aggregation of amyloid and tau (Reiman et al., 2009 and 
Holtzman et al., 2000). ε4 allele is specifically associated with increased 
amyloid burden and cholinergic neurotransmission dysfunction. Individuals 
who inherit two ε4 alleles are at seven times higher risk of developing AD 




during an individual’s mid-life is considered a risk factor for AD and statins 
have shown reduced risk of developing AD (Kivipelto et al., 2001).   
 
1.2.5 ATP and its metabolites in AD  
Many neurological disorders, including AD can evoke inflammatory 
response to pathogenic agents or insults. Activated astrocytes (Norton et al., 
1992) and microglia (Graeber et al., 2011) are recognized as the key cellular 
regulators of innate immune system in adult brain. Being the first line of 
defense in CNS, microglia react quickly to a wide variety of substances 
released from damaged CNS cells and foreign substances (Kreutzberg, 1996, 
Streit, 2000). Extracellular purines, especially ATP, have been known to be a 
potent activator of microglia. During any pathological insult such as 
inflammation, ischemia, hypoxia or trauma, ATP is released and/or leaked into 
extracellular space. The sources of ATP include nerve terminals, the lysed and 
damaged cells and activated immune cells such as astrocytes (Inoue et al., 
1998). Extracellular ATP acts upon the cell surface P2 purinergic receptors 
which are further classified into P2X and P2Y receptors. P2X subtype are 
ligand gated ion-channels while P2Y subtypes are G protein coupled receptors 
(GPCRs) with seven transmembrane domains (Ralevic and Burnstock, 1998). 
So far, 7 P2X and 8 P2Y receptor subtypes have been identified in different 
cell types of CNS. Due to such functional complexity, the studies of functions 
of P2 receptors in CNS are considered as combined contribution of P2X and 
P2Y receptors expressed in all major CNS cell types including neurons, 





After release, ATP undergoes rapid enzymatic degradation by various 
ectonucleotidases. Adenosine, a purine ribonucleoside, is the final product of 
this breakdown (Zimmermann, 2006). One of the major endogenous ligands, it 
acts via four GPCRs i.e. A1A, A2A, A2B and A3. A1A and A3 receptor 
subtypes are coupled to Gi/o, inhibiting adenylyl cyclase (AC). On the other 
hand, A2A and A2B subtypes are coupled to Gs protein, stimulating AC 
(Fredholm et al., 2005). Adenosine acts an important neuromodulator in CNS, 
regulating neuronal excitability, synaptic transmission and synaptic plasticity 
(Cunha, 2001). Adenosine signaling has long been considered as a drug 
development target against all major neurodegenerative diseases (Abbracchio 
and Cattabeni, 1999). In fact, definitive role of adenosine has been highlighted 
in almost all major neurological diseases like AD (Albasanz et al., 2008), PD 
(Fuxe et al., 2010), Pick’s disease (Albasanz et al., 2006), Huntington’s 
disease  (Blum et al., 2003), and Schizophrenia (Boison et al., 2012). In 
connection to AD, adenosine metabolism is very critical. The extracellular 
concentration of adenosine is firmly kept under check by various enzymes 
such as adenosine kinase (Boison, 2006) in physiological conditions. As 
discussed earlier in this thesis, oxidative stress is considered as an important 
pathogenetic factors of AD. Many studies suggest that the oxidative stress 
culminates into neuronal trauma and degeneration in the brain of AD patients 
(Markesbery, 1997, Christen, 2000). In this process, the exquisite balance of 
adenosine nucleotides and nucleosides is disrupted resulting into altered ATP-
ADP ratio (Headrick and Willis, 1990, Park and Gupta, 2013). The elevated 
ADP concentration leads to increased activity of adenylate kinase enzyme. In 




augmented. (Ballard, 1970). More and more adenosine is generated from the 
hydrolysis of excess AMP. (Decking et al., 1997). Excessive intracellular 
adenosine is liberated from the cell to raise the extracellular concentration of 
adenosine (Park and Gupta, 2013).  
 
1.2.6 Diagnosis and clinical symptoms of AD 
1.2.6.1 Classification and Diagnostic criteria 
The classification and the criteria used to diagnose dementia and AD is 
set out in the Diagnostic and Statistical Manual of Mental Disorders (4th ed, 
text revision, DSM-IV-TR) (APA) and the International Statistical 
Classification of Diseases and Health-related Problems, 10th revision (ICD-10) 
(WHO, 2010). The DSM-IV-TR (APA) and ICD-10 classifies dementia as 
memory impairment with one or more impairment(s) in other cognitive 
domains. 
  The ICD-10 defines AD as “a primary degenerative cerebral disease of 
unknown etiology with characteristic neuropathological and neurochemical 
features. The disorder is usually insidious in onset and develops slowly but 
steadily over a period of several years”(WHO, 2010). The DSM-IV-TR does 
not use the term AD, and instead uses dementia of the Alzheimer’s type 
(DAT). DAT is a manifestation of “early deficits in recent memory followed 
by the development of aphasia, apraxia, and agnosia after several years (APA). 
The ICD-10, classifies Alzheimer’s disease as early and late onset. There is 
also as a classification for mixed type, this is where Alzheimer’s disease may 




also classifies the DAT as early onset (65 years or below) and late onset (65 
years or above) (APA). The DM-IV-TR further categorizes DAT of the two 
groups based on the presence or absence of predominant non-cognitive 
symptom. These symptoms are delirium, delusions and depressed mood, or an 
uncomplicated DAT (APA). 
The National Institute of Neurological and Communicative Disorders 
and Stroke-Alzheimer Disease and Related Disorders Association (NINCDS-
ADRDA) criteria (McKhann et al., 1984) is another criteria which is used in 
the clinical diagnosis of AD. This NINCDS-ADRDA criterion is regarded as 
the gold standard for diagnostic purposes. Patients are categorized as having 
probable, possible or definite (post-mortem confirmation) AD. 
For research purposes the accepted diagnosis of AD is usually based 
on the DSM-IV-TR and the NINCDS-ADRDA criteria. The application of the 
criteria is a two-step process, whereby in the first step an initial identification 
of a dementia is made, followed by step 2, where the criteria is applied using 
the clinical features of the AD phenotype (Dubois et al., 2007). Knopman and 
colleagues reported that over 90% of patients diagnosed with AD ante-mortem 
using the current criteria were found to have AD pathology post mortem 
(Knopman, 2001). 
1.2.6.2 Clinical symptoms and the course of the illness 
The main cognitive symptoms of AD are amnesia, aphasia, apraxia, 
agnosia, and executive dysfunction. Over the course of the illness these 
symptoms become more pronounced, owing to an increase in disease severity. 
There are also non-cognitive symptoms that are prominently manifested 




symptoms. Symptoms such as agitation, apathy, depression, hallucinations and 
delusions occur at some stage in most patients. They cause significant distress 
to both patients and their carers and lead to early institutionalization of 
patients. An additional impact of AD is on the day to day activity of patients 
(activities of daily living). These symptoms result in adverse effects of quality 
of life, impact on caregiver burden (Gonzalez-Salvador et al., 2000), and cost 
of care (Murman and Colenda, 2005). 
Overall evaluation of dementia therefore falls into six broad categories, 
historical, cognitive, behavioral, functional, motor & medical (see table 3). 
Symptoms are graded as mild, moderate and severe, and are assessed 
clinically using scales. The scales are used to assess and monitor symptoms 
















Language, attention, learning 
and memory 
Cognitive evaluation: 
AD Assessment scale- 
Cognitive (ADAS-Cog), 







apathy, depression, anxiety, 
agitation 
Behavioral 
Disturbances- NPI and 
the BEHAVE-AD 
Functional Daily activities (ADL) Functioning: ADL 
Motor Daily activites (ADL) Functioning: ADL 
Medical 
Dysfunction: hyper or 
hypokinetic and neurological 
signs. 
Identifying risk factors 
 
 
Table 3 Evaluation of dementia 
The evaluation of dementia falls into six broad categories, historical, cognitive, 
behavioral, functional, motor & medical are used to capture a full a picture of the 
extent of dementia both physically and mentally. Data is reproduced from (Kwentoh, 
2008) with some modifications. 
 
1.2.7 Pharmacotherapy 
Current treatments for AD are used to reduce the cognitive decline. 
The central role of these drugs is to stabilize and thus minimize disruption of 
two key neurotransmitters, acetylcholine (ACh) (the cholinergic hypothesis of 
Alzheimer’s disease), and glutamate. AChE inhibition is used to protect the 
cholinergic neurons and glutamate (Klafki et al., 2006). A number of 
treatments are also used to alleviate neuropsychiatric symptoms, including 
anti-depressants and anti-psychotics. Anti-psychotics are largely used to treat 
agitation, aggression and psychosis. 
The three compounds which work on the basis of AChE inhibition are 




compounds are efficacious in reversing and improving memory and global 
cognition, in mild to moderately demented patients (Birks, 2006). The second 
key transmitter targeted is glutamate, the primary excitatory neurotransmitter 
in the brain. The interaction of glutamate with the N-methyl-D-aspartate 
(NMDA) receptor is important in the workings of memory and learning. In 
AD an increase in glutamate activity results in NMDA receptor being 
excessively activated which may lead to neurodegeneration (Klafki et al., 
2006). Consequently memantine, an NMDA antagonist, is used to counter the 
loss or damage of NMDA receptors due to excess glutamate excitation in AD 
patients. Targeted primarily at moderate to severely demented patients, 
memantine is considered to overall reduce burden of care on the carer, as well 
as clinically reversing and improving memory and global cognition, reducing 
behavioural disturbances, and improvement in the quality of life (Areosa et al., 
2005, Wilcock, 2003). 
Several drugs and therapeutical strategies are being developed 
targeting cerebral amyloid generation in AD. They either inhibit the 
production of Aβ or escalate its clearance in the brain. The most common 
mechanisms of action of these drugs are the inhibition of the rate limiting 
steps of Aβ generation i.e. β- and/or γ- secretases processing of APP (Citron, 
2010). Although the reasoning behind this approach is rational, no drug has 
shown consistent benefit to the AD patients (De-Paula et al., 2012). Initially, 
the β- and/or γ- secretases inhibitors showed promising disease modifying 
effects for AD (Panza et al., 2009). These therapeutic agents lessened the 
amyloid burden in brain and improved cognition deficit in transgenic mice 




2007, Lahiri et al., 2007). Furthermore, the slight but significant 
improvements in cognition of mild to moderate cases of AD during phase I 
and II clinical studies (Fleisher et al., 2008, Coric et al., 2012) encouraged 
phase III clinical trials with these drugs . However, these drugs did not slow 
down cognitive decline or the loss of activities of daily living in patients with 
mild AD (Green et al., 2009). Increasing the dosage resulted in significant 
worsening of functional ability associated with more adverse events, including 
skin cancers and infections (Doody et al., 2013). 
The immunotherapeutical approach is yet another extensively studied 
strategy for AD treatment. It can be divided under two broad categories; active 
and passive immunotherapies. In active immunotherapy, the anti-amyloid 
vaccines activate immune system (i.e. glial cells in brain) against soluble 
amyloid species as well as amyloid aggregates. This sensitization improved 
amyloid clearance in the brain of hAPP transgenic mice (Schenk et al., 1999). 
Preclinical studies done in AD animal models demonstrated a little but 
significant improvements in cognitive decline due to improved clearance of 
amyloid burden and its redistribution from brain to systemic circulation (Janus 
et al., 2000, Morgan et al., 2000, Sha et al., 2014). Bolstered by these positive 
results, the first ever clinical trial was conducted. However, the clinical trial 
was terminated at its second stage due to the adverse neuroinflammatory 
reactions (meningoencephalitis) shown by subjects receiving the vaccine 
(Orgogozo et al., 2003). Although the administration of vaccine did not show 
any significant cognitive improvements in the patients, the follow-up 
neuropathological examination revealed a significant lowering of amyloid 




equally effective in preclinical studies as it reduced Aβ burden and improved 
cognitive decline in the animal models (Wilcock et al., 2004, Lee et al., 
2006a). Passive immunotherapy does not activate microglia thus chances of 
adverse neuroinflammatory reactions are low (Roher et al., 2011, Lichtlen and 
Mohajeri, 2008) . Phase II clinical trials demonstrated significant enhancement 
in cognitive capabilities of patients without adverse neuroinflammatory events 
(Okello et al., 2009). However, Movsesyan et al doubts the overall 
effectiveness and practicability of using passive vaccination due to cost and 
invasive nature of the treatment and reluctance of patients to visit the clinics 
frequently hampering the effective delivery of the immunotherapy 
(Movsesyan et al., 2008a, Movsesyan et al., 2008b, Sha et al., 2014). 
Collectively, further refinement of vaccines for AD is needed to eliminate, or 
at least attenuate the potential adverse events. 
 
1.3 Objectives 
Although extensive studies have been performed to investigate therapeutic 
properties H2S, our knowledge about the underlying signaling pathways is still 
incomplete. The evidences derived from cell and animal models of AD 
suggested that purinergic signaling by ATP and its metabolites is important in 
context of AD pathology. Additionally, ATP and its metabolites are up-
regulated in the brain parenchyma under pathological insult.  
With this information in hand, the focus of the current study is to 




the associated underlying mechanisms. More particularly, this study sought to 
examine: 
• Effect of H2S on Aβ synthesis in SH-SY5Y neuroblastoma cells 
transfected with APP Swedish mutation (an established cell model of 
AD). The cells will be incubated with A2A receptor agonist, 
HENECA. 
• Effect of H2S on glutamate excitotoxicity caused by astrocytes.  As we 
will also be investigating the link between A2A receptors and 
glutamate uptake, the cells will be incubated with A2A receptor 
agonist, HENECA. 
• Effect of H2S on neuroinflammation and subsequent amyloidosis in 
extracellular ATP stimulated immortalized BV-2 cells. 
• The elaborate study of underlying signaling pathways in each of the 
































2.1 Chemicals  
Sodium hydrosulfide (NaHS), forskolin, 3-isobutyl-1-methylxanthine 
(IBMX), SQ22536, ZM241385, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester (DAPT), dichlorofluorescin diacetate and 
methylthiazolyl tetrazolium (MTT) were purchased from Sigma Aldrich (St. 
Louis, MO, USA). 2-Hexynyladenosine-5'-N-ethylcarboxamide (HENECA) 
was ordered from Abcam (Cambridge, MA, USA). The specific cathepsin S 
inhibitor was ordered from Calbiochem. SC203282 was ordered from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). NaHS, HENECA, SQ22536, 
ATP and MTT were dissolved in de-ionized water, while forskolin, ZM 
241385, IBMX, DAPT, the specific cathepsin S inhibitor and SC203282 were 
dissolved in dimethylsulfoxide (DMSO). Primary antibodies against phospho-
CREB, Adenosine A2A-R, iNOS, COX-2, GLAST and β-actin were 
purchased from Santa Cruz biotechnology (St. Louis, MO, USA). Monoclonal 
antibody against APP (clone 22C11) and polyclonal antibody against APP C-
terminus were from Millipore (Temecula, CA, USA).  
NaHS was used as an H2S donor. When NaHS is dissolved in water at 
neutral pH, HS− is released and forms H2S with H+. This provides a solution of 
H2S at a concentration that is about 33% of the original concentration of NaHS 
(Reiffenstein et al., 1992).  
2.2 Cell Culture and Treatments 
 Many in vivo, ex vivo and in vitro disease models have been produced 
to study underlying mechanisms for pathology of various neurodegenerative 




models. The scientists have been able to mimic the intra and extra cellular 
environment of a particular disease and investigate the contribution of one 
specific cell type in that disease pathology. Furthermore, the cell lines have 
been proven excellent tools to study the mechanisms behind potential harmful 
or beneficial effects of many natural or synthetic molecules (Schlachetzki et 
al., 2013).   
We used well-accepted SH-SY5Y human neuroblastoma cell line, 
which is originally derived from biopsy of metastatic bone tumor. This cell 
line is the result of successive 3-times subcloning of the parental SH-N-SH 
line (Kovalevich and Langford, 2013). These cells can be transfected with 
wild-type or mutant forms of APP and/or tau. Many pathological features of 
AD, such as amyloidogenesis, neuronal dysfunction and cell loss can be 
studied in SH-SY5Y cells (Schlachetzki et al., 2013). It is now commonly 
believed that glial cells play an undisputed role in AD pathology. We 
employed BV-2 microglial cell lines in our experiments. This cell line has 
been generated by infecting primary microglial cell cultures with a -raf/v-myc 
oncogene carrying retrovirus and are the most frequently used substitute for 
primary microglia (Blasi et al., 1990). These cells have been fully 
characterized using proteomics analysis and in vivo microglia analysis. These 
findings have been supported by the data from study of 500 inflammation-
related genes analyzed by competitive hybridization. All studies indicate their 
high similarity to primary microglial cells (Henn et al., 2009). It should also be 
mentioned here that BV-2 cells are easy to subculture and thus provide an 




The SH-SY5Y and BV-2 cell lines were obtained from the American 
Type Culture Collection (Manassas, VA, USA). Both cell types were cultured 
in 75 cm2 flasks in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin (100 
U)/streptomycin (100 mg/mL), and were maintained at 37°C in an incubator 
under a humidified atmosphere of 95% air and 5% CO2. Cells were split twice 
a week. The cells were seeded at a density of 5X105 cells/well in 6-well plates 
a day before the transfection. The SH-SY5Y cells were lipotransfected with 
pcDNA4-hAPP695swe using the Lipofectamine 2000 transfection reagent. 
After transfection for 24 hours, cells were treated with different chemicals 
mentioned above. This plasmid was a kind gift from Dr. Weihong Song, 
University of British Columbia, Vancouver, Canada. HEK-293 Cells were 
transfected with either pcDNA3-cathepsin S (WT-HEK) or pcDNA3-cathepsin S-
C25S cDNAs. 
For each experiment, confluent cells in 75-cm2 flasks were seeded onto 
35-mm dishes. Cells in culture dishes were used for experiments after reaching 
80-90% confluence. 
2.3 Constructs and Mutagenesis 
The construct of cathepsin S was kindly provided by Dr. Hyun-Shik of 
School of Life Science and Biotechnology, College of Natural Sciences, Kyungpook 
National University, Republic of Korea. Site directed mutagenesis was performed 
with the Quick change site-directed mutagenesis kit from Stratagene with name of the 
plasmid as template. Cys residues (C25, C216) on cathepsin S were substituted for 





2.4 Preparation of Primary Astrocyte Culture 
The protocol was approved by the animal ethics committee of National 
University of Singapore and conducted in accordance with established 
Guiding Principles for Animal Research. 
Primary astrocyte cultures was prepared from the cortices of newborn 
(1-2-days old) Sprague Dawley (SD) rats as stated by Gao et al. (Gao et al., 
2002) with few modifications. Briefly, cortical tissue were ground and 
digested with 0.25% trypsin. Cells were then separated by gentle mechanical 
trituration and cultured in DMEM supplemented with 10% FBS, 2 mM L-
glutamine, 1% MEM non-essential amino acid solution, 10 µg/ml insulin, 1% 
penicillin/streptomycin. The cells were kept in incubator at 37ºC with 5% 
CO2/95% with humidified atmosphere. The medium was replaced every three 
days. In about 2 weeks, the cells reached confluence. The microglia were 
separated from the underlying astrocytic monolayer by orbital shaking at 250 
rpm for 90 min because of their differential adhesive properties. The floating 
microglia were discarded. After removal of the microglia, the remaining glial 
cells were washed twice with PBS and re-cultured in DMEM. These cells 
were considered as purified astrocytes. The purity of the astrocytes was 
determined by staining with anti-GLAST, an astrocyte specific marker. 
Immunostaining analysis shows that this method produces cultures comprising 
>95% GLAST-positive astrocytes. 
2.5 Cell Viability Assay 
 Cell viability was assessed by MTT reduction assay as follows. At the 




37°C with MTT at a final concentration of 0.5 mg/ml for 4 hours. The purple 
formazan formed was solubilized with 150 µL DMSO. The absorbance of the 
colored solution was measured at 570 nm with a reference wavelength of 630 
nm using Saffire 2 microplate reader (Tecan, USA). 
2.6 Intracellular cAMP Assay 
 A commercially available direct cAMP enzyme immunoassay kit 
(Cayman Chemical, USA) was used to examine the involvement of cAMP. 
Briefly, cells were incubated in DMEM containing 0.5% FBS. After treatment 
with different drugs described in results section, the cells were lysed in 0.1 M 
HCl for 20 minutes. 50 µL of samples were added into a 96-well plate 
followed by incubation with cAMP acetylcholine esterase tracer and cAMP 
antiserum for 18 hours at 4°C. Each sample was developed with Ellman's 
reagent next day and the plate was read at a wavelength of 405 nm. cAMP 
concentration was calculated according to the cAMP standard and the protein 
was quantified by dissolving the pellets. 
2.7 Cell Fractionation and Adenylyl Cyclase (AC) Activity Assay 
A cell fractionation technique was adopted from the literature (Mackay 
and Mochly-Rosen, 2001). AC activity was assayed as described previously 
(Pan et al., 2008, Yong et al., 2008) with some modifications. The AC activity 
assay was performed at 37°C for 10 min in a 400 µL reaction mixture 
containing 1 mM ATP, 100 mM NaCl, 50 mM HEPES, 0.5 mM IBMX, 6 mM 
MgCl2, 1 µM GTP, and 20 µg of membrane protein. Reactions were stopped 
by addition of 0.6 mL of trichloroacetic acid (10% w/v). The accumulation of 




2.8 γ-secretase (Fluorogenic Substrate) Assay 
The assay was performed as described previously in the literature 
(Farmery et al., 2003). Briefly, the cell lysates were centrifuged at 12000 g for 
15 min. Resultant pellets were resuspended and incubated overnight at 37°C in 
200 mL of assay buffer containing 10 µL fluorescent substrate of γ-secretase 
(Calbiochem). The fluorescence was measured with excitation wavelength set 
at 355 nm and emission wavelength at 440 nm.   
2.9 ELISA for Aβ42 
 The conditioned medium from samples was collected by centrifugation 
(12,000 g at 4°C for 15 min). The secreted levels of Aβ42 in conditioned 
medium were quantitatively measured by commercially available ELISA kit 
(Invitrogen, USA). Briefly, the samples were diluted by standard diluent 
buffer and AEBSF was added to diluted samples and standards which prevent 
proteolysis of Aβ peptides. The standards, controls and samples were pipetted 
into the antibody pre-coated wells and co-incubated with a rabbit antibody 
specific for the C-terminus of the 1-42 Aβ sequence. Bound rabbit antibody 
was detected by the use of a horseradish peroxidase-labeled anti-rabbit 
antibody.  After washing, horseradish peroxidase-labeled anti-rabbit antibody 
(enzyme) was added. After washing to remove the entire unbound enzyme, a 
substrate solution was added, which is acted upon by the bound enzyme to 
produce color. The intensity of this colored product is directly proportional to 
the concentration of Aβ42 present in the samples. The optical density was 





2.10 Reactive Oxygen Species (ROS) Measurement 
Formation of reactive oxygen species (ROS) was evaluated using non-
fluorescent dye 2′, 7′- dichlorofluorescin diacetate (DCFH-DA), which freely 
penetrates cells and yields the highly fluorescent product dichlorofluorescein 
(DCF) by ROS oxidation. Following ATP and/or NaHS treatment, cells were 
rinsed with PBS solution and incubated with Hank’s Buffered Salt Solution 
(HBSS) containing DCFH-DA dye (10 µM final concentration) 30 minutes in 
the dark. The fluorescence was read immediately for 1 h, at an excitation 
wavelength (Ex) of 490 nm and an emission wavelength (Em) of 520 nm. 
2.11 Measurement of Nitric Oxide 
Nitrite was detected in the culture supernatant using a commercial kit 
(Promega, Madison, WI, USA). In accordance with the manufacturer's 
instructions, 50 µL aliquots of cell culture medium from each dish were 
collected and mixed with 100 µL of Griess reagent (50 µL of 1% 
sulfanilamide + 50 µL of 0.1% naphthylethylenediamine dihydrochloride in 
2.5% H3PO4) in a 96-well microtiter plate. The absorbance was read at 530 nm 
using a plate reader (Tecan, USA). 
2.12 ELISA for TNF-α and IL-Iβ 
For TNF-α and IL-Iβ assay, culture medium was detected by using a 
commercial enzyme-linked immunoassay kit (BD Biosciences, San Diego, 
CA, USA). 
2.13 DNA binding activity assay 
The DNA binding activity was quantified using a commercially 




according to the manufacturer's instructions. In short, the CTFB was prepared 
and added to sample wells. 10 µL of competitor dsDNA, positive control and 
samples were added to appropriate wells. The wells were kept in 4oC 
incubation overnight. Next day, after washing of wells with wash buffer, 100 
µL of diluted NF-κB was antibody was added to each well. After incubation at 
room temperature for one hour, 100 µL of secondary antibody was added. The 
cells were washed after incubation for 1 hour at room temperature. After 
addition of developing solution and stop solution, absorbance values were 
measured at 450 nm. 
2.14 Cathepsin S activity assay 
The cathepsin S activity was quantified using a commercially available 
flurometric cathepsin S activity assay (Abcam) according to the 
manufacturer's instructions. 
2.15 S-sulfhydration assay (modified biotin switch) 
The assay was performed as described previously (Mustafa et al., 
2011, Mustafa et al., 2009) with minor modification. Briefly, cells were 
homogenized by sonication in the HEN buffer (250  mM Hepes-NaOH pH 7.7, 
1  mM EDTA, and 0.1  mM neocuproine) supplemented with 100  µM 
deferoxamine and centrifuged (13,000 g, 30  min, 4°C). Cell lysates were 
treated with different NaHS (37°C, 30  min) followed by a 30-min incubation 
with or without 2  mM idoacetamine. The blocking buffer (2.5% SDS HEN 
buffer and 20  mM MMTS) was then added (50°C, 20  min) and the MMTS was 
removed by precold acetone (−20°C, 20  min). After removal of acetone 




(adjusted to 1% SDS). Leaving a part of the mixture as control (input), the 
remaining was added with 1  mM biotin-HPDP and incubated at 25°C for 3  h. 
Finally, the biotinylated proteins were precipitated by streptavidin-agarose 
beads, eluted by the SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
sample buffer, and subjected to Western blot alongside the input. 
2.16 Glutamate uptake assay 
 The glutamate concentrations were quantified using a commercially 
available colorimetric (optical density at 450 nm) glutamate assay kit (Abcam) 
according to the manufacturer's instructions. 
2.17 Reverse Transcription-PCR 
Two-step reverse transcription polymerase chain reaction was used to 
determine mRNA levels of AC1, AC3, AC8, PS1, PS2 and GAPDH in SH-
SY5Y cells. Total RNA was extracted using TRIzol® extraction method 
(Invitrogen, Carlsbad, CA, USA). Homogenized samples were then incubated 
at room temperature for 10 min. Chloroform was added and tubes were shaken 
vigorously by hand for 15 min followed by incubation for 3 min at room 
temperature again. Samples were centrifuged at 12000 g for 15 min at 4°C. 
Colorless upper aqueous phase was transferred to a new tube containing 
isopropanol (prepared in nuclease free water) and incubated for 10 min at 
25°C followed by centrifugation at 12000 g for 10 min at 4°C. Supernatant 
was discarded and RNA pellets were washed with 70% ethanol (prepared in 
nuclease free water). RNA concentration was determined with NanoDrop 
Spectrophotometer (ND-1000, NanoDrop Technology). Equal amounts of 




cDNA synthesis kit (Bio-Rad). Reverse transcription was performed at 25°C 
(for 5 min), 42°C (for 30 min) and 85°C (for 5 min). The resulting cDNAs 
were PCR-amplified using Taq DNA polymerase kit (i-DNA Biotechnology). 
The specific PCR primer sequences used were as follows:  
AC1 (5’-CATGACCTGCGAGGACGAT-3’ and 5’-
TCCCGTTCGACATGTTTGTA-3’)  (Kolachala et al., 2005),  
AC3 (5’-GTACTACACGGGACCCAGCA-3’ and 5’ –
GCTCTAAGGCCACCATAGGTA-3’) (Kolachala et al., 2005),  
AC8 (5’-ACCGGCATTGAGGTAGTGAT-3’and 5’- 
ATGACCACTTGGAGGATGAC-3’)  (Kolachala et al., 2005),  
PS1 (5’-ACAGAGTTACCTGCACCGTTGTCC-3’ and 5’-
TTCCTCATCTTGCTCCAC-CACCTG) (Satoh and Kuroda, 1999), 
PS (5’-AGTGAGAGA-CAGCCAGAAGCAAG-3’ and  
5’-AACCCCACTACAGACATAGCGGTC-3’) (Satoh and Kuroda, 1999), 
 GADPH (5’-GCGGGGCTCTCCAGAACATCAT-3’ and  
5’-GGTGTC-CAGGGGTCTTACTCC-3’) (Canals et al., 2005)  
PCR conditions were set as 95oC (for 30 sec), 55oC (for 30 sec), and 72oC (for 
30 sec) for 40 cycles. PCR products were separated on a 1% agarose gel and 
stained with ethidium bromide. The optical densities of the mRNA bands were 




2.18 Western Blot Assay 
Cells were washed twice with ice-cold PBS after treatment and 
solubilized in RIPA lysis buffer (150 mM sodium chloride, 1.0% Nonidet P-
40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris at pH 8.0, protease 
and phosphatase inhibitor cocktails). The cell lysates were shaken and kept on 
ice for 1 hour before being subjected to centrifugation at 12,000 g at 4°C for 
10 min. Supernatants were collected and denatured by SDS sample buffer. 
Epitopes were exposed by boiling the protein samples at 95°C for 5 min. 
Protein concentrations were determined with a NanoDrop Spectrophotometer 
(ND-1000, NanoDrop Technology). Equal amounts of the protein samples 
were separated by electrophoresis using a 10% sodium dodecyl sulphate-
polyacrylamide (SDS/PAGE) gel and transferred onto a nitrocellulose 
membrane (Whatman®, Germany). After being blocked in 10% milk with 
TBST buffer (10 mM Tris-HCl, 120 mM NaCl, 0.1% Tween-20, pH 7.4) at 
room temperature for 1 hour, the membranes were incubated with respective 
primary antibodies at 4°C overnight. Membranes were washed three times in 
TBST buffer, followed by incubation with 1:10000 dilutions of appropriate 
horseradish peroxidase-conjugated (HRP) anti-mouse IgG, anti-goat or anti-
rabbit IgG at 25°C for 1 hour, and washed three times in TBST. Visualization 
was carried out using ECL® (plus/advanced chemi-luminescence) kit (GE 
healthcare, UK). The density of the bands on Western blots was quantified by 
Image J software. 
2.19 Statistical Analysis 
Values stated are mean ± SEM of at least triplicate measurements. 




variance (ANOVA) followed by a post hoc (Bonferroni) test for multiple 




























3 Hydrogen sulfide inhibits A2A adenosine receptor agonist induced β-
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 AD is the most common neurodegenerative disease in the world (Reitz 
et al., 2011a). The worldwide prevalence of AD in aged population is on the 
exponential rise, affecting worst in the age group above 85 years (Castellani et 
al., 2010). AD has all set to become one of the most crippling diseases in 
upcoming decades with dire economic and social upshots. 
The characteristic pathological features of AD encompass deposition 
of senile plaques, neurofibrillary tangles, neurodegeneration and resultant loss 
of synaptic function (Selkoe, 2002, Mattson, 2004). Senile plaques are made 
of Aβ peptides, which in turn are biologically active products of larger 
amyloid precursor protein (APP) integrated in plasma membrane (Selkoe, 
1991). In the predominant non-amyloidogenic APP processing pathway, APP 
is split within the transmembrane region by α-secretase, precluding Aβ 
synthesis. In the process, soluble N-terminal fragment (sAPPα) is yielded 
which is involved in many neuroprotective mechanisms such as genesis and 
survival of neurons. In amyloidegenic pathway, APP is split first by β-
secretase yielding sAPPβ and CTF β. The membrane attached β-CTF is then 
acted upon by γ-secretase to generate Aβ  (Cummings et al., 1998). The 
above-mentioned amyloid hypothesis strongly support that APP metabolism is 
crucial step in AD pathogenesis.  Hence targeting APP processing is one of the 
key strategies to combat AD.  
Neuropsychiatric symptoms are core features of AD (Lyketsos et al., 
2011) as chronic neurodegeneration alters various important brain functions 
like cognition and memory. Many of these brain functions are controlled by 




functions. Its signaling is considered as a potential therapeutic target for major 
neurological disorders. 
 The role of H2S as a modulator in many physiological systems 
including CNS has been extensively studied (Bhatia et al., 2005, Jeong et al., 
2006, Lee et al., 2006b). The influence of H2S on intracellular [Ca2+]i 
homeostasis is already discussed in the introduction section of thesis. H2S has 
also been reported to stimulate KATP channels, which play a mediator role in 
the process of release of neurotransmitters from presynaptic neurons and also 
protects neurons during hypoxic insult (Yamada and Inagaki, 2005, Tan et al., 
2010). H2S also maintains neurotransmission by keeping excitatory-inhibitory 
balance (Hu et al., 2011).  H2S upregulates γ-aminobutyric acid B receptors 
(GABABR) thus fine tuning inhibitory neurotransmission and regulation of 
the neurotransmitters release from presynaptic neurons (Qu et al., 2008). H2S 
is well known modulator of long-term potentiation (LTP) in active 
interneuronal synapses and communication between neuron and glial cells 
(Abe and Kimura, 1996, Lee et al., 2006b). This gasotransmitter targets 
various ion channels, protein kinases and transcription factors, during its 
action as a cell signaling mediator (Li et al., 2011). The protective and 
favorable effects of H2S have already been reported in disease models of PD 
(Hu et al., 2010), severe neuroinflammation (Hu et al., 2007b) and oxidative 
stress induced neuronal injury (Lu et al., 2008). In this section, the inhibitory 







3.2 Materials and Methods 
3.2.1 Chemicals 
 Please refer to section 2.1 
3.2.2 Cell Culture and Treatments 
Please refer to section 2.2 
3.2.3 Cell Viability Assay 
 Please refer to section 2.5 
3.2.4 Intracellular cAMP Assay 
 Please refer to section 2.6 
3.2.5 Cell Fractionation and Adenylyl Cyclase (AC) Activity Assay 
 Please refer to section 2.7 
3.2.6 γ-secretase (Fluorogenic Substrate) Assay 
 Please refer to section 2.8 
3.2.7 ELISA for Aβ42 
 Please refer to section 2.9 
3.2.8 Reverse Transcription-PCR 
 Please refer to section 2.17 
3.2.9 Western Blot Assay 





3.2.10 Statistical Analysis 
 Please refer to section 2.19 
 
3.3 Results 
3.3.1 NaHS attenuates adenosine A2A receptor agonist stimulated Aβ42 
production 
HENECA, a selective adenosine A2A receptor agonist (10-200 nM, 24 
hours), stimulated the production of Aβ42 by SH-SY5Y neuroblastoma cells 
in a dose-dependent fashion (Fig 3.1A). The cells were transfected with APP 
Swedish mutation to elevate the basal production of Aβ42 (Tomita et al., 
1998). NaHS pretreatment at 10-200 µM for 12 hours notably abolished the 
Aβ42 production triggered by HENECA (100 nM) in a dose-dependent 
manner (Fig 3.1B). Nonetheless, NaHS pretreatment (50-100 µM) alone did 
not alter the basal production of Aβ42 notably (Fig 3.1C). MTT cell viability 
assays were done to exclude the possibility of lethal effects of NaHS and 
HENECA. MTT results demonstrated that neither NaHS (Fig 3.1D) nor 
HENECA (Fig 3.1E) at the doses used in this study had any influence on cell 
viability. Hence, 100 µM concentration of NaHS was used in all other 
experiments in this study or otherwise stated. This particular concentration is 
non-physiological as serum concentration of H2S in normal humans spanning 




















Figure 3.1 Effects of NaHS on Aβ42 synthesis and cell viability in APPswe 
transfected SH-SY5Y cells. 
A: HENECA (10-200 nM, 24 h) dose-dependently increased Aβ42 synthesis. B-C: 
Concetration-dependent effect of NaHS (10-200 µM, 12 h) on Aβ42 synthesis with 
(B) or without (C) HENECA (100 nM, 24 h). D-E: The effects of NaHS alone (10-
200 µM) (D) or HENECA alone (10-200 nM) (E) on cell viability of SH-SY5Y cells, 
as shown by cell viability assay.  Aβ42 levels in cell culture media were quantified by 
sandwich ELISA kit. Control values were converted to 100%. Values are presented as 
means ± S.E.M, n= 6. ## p < 0.01, ### p < 0.001 vs Control group; ** p < 0.01, *** p 
< 0.001 vs HENECA group. Con:Control, HEN: HENECA. Figures taken from 




3.3.2 The involvement of cAMP/PKA/CREB pathway in the inhibitory 
effect of NaHS on HENECA-stimulated Aβ42 production 
In this part, we attempted to find the underlying signaling mechanism 
for the effects of NaHS. As demonstrated in Fig 3.2A, HENECA at 1-100 nM 
concentration (in a concentration-dependent manner) elevated intracellular 
cAMP levels. NaHS (10-200 µM) dose-dependently reversed the intracellular 
cAMP levels augmented by HENECA (Fig 3.2B). However, NaHS at 100 µM 
alone did not affect cAMP production notably (Fig 3.2B). In order to test 
whether NaHS targeted the cAMP synthesis or its decomposition, following 
experiments were conducted. The intracellular cAMP production was raised 
by increasing its synthesis by forskolin (AC agonist) and by inhibiting its 
decomposition by IBMX (a phosphodiesterase antagonist). As evident from 
Fig 3.2C, NaHS notably inhibited the increased cAMP synthesis caused by 
either forskolin alone or forskolin with IBMX, but had not affected that caused 
by IBMX alone. In addition, NaHS pretreatment notably inhibited the 
production of Aβ42 activated by forskolin with or without IBMX, but did not 
affect that caused by IBMX alone (Fig 3.2D).  
Inhibiting PKA with H-89, its selective inhibitor, at 5-15 µM 
concentration also abated the Aβ42 production induced by HENECA (Fig 
3.2E). To check whether CREB was also involved, we determined CREB 
phosphorylation by western blotting. As evident from Figs 3.2F and 3.2G, 
NaHS pretreatment notably inhibited HENECA-induced CREB 
phosphorylation. These data confirm that the suppressive effect of H2S on 




























Figure 3.2 The involvement of cAMP signaling pathway in the observed effects of 
NaHS on Aβ42 production. 
A: Concentration-dependent effect of HENECA on cAMP synthesis in APPswe 
transfected SH-SY5Y cells. B:  Dose-dependent effect of NaHS (10-200 µM, 12 h) 
on HENECA (100 nM, 24 h)-stimulated cAMP production. C-D: Inhibitory effects of 
NaHS (100 µM) on cAMP (C) and production of Aβ42 (D) in cells incubated with 
forskolin (20 µM) and/or IBMX (100 µM). E: The stimulatory effect of HENECA 
(100 nM) on Aβ42 production was negated by H89, a PKA inhibitor (5, 10 and 15 
µM). F-G: The pretreatment with NaHS (100 µM, 12 h) abolished the effects of 
HENECA (100 nM, 24 hours) on CREB phosphorylation. The intracellular cAMP 
and Aβ42 levels in cell culture media were quantified by sandwich ELISA kits. 
Control values were converted to 100% for Aβ42 production measurement. Values 
are presented as means ± S.E.M, n=4-6. ### p < 0.001 vs Control group, ** p < 0.01, 
*** p < 0.001 vs HENECA group,+++ p < 0.001 vs Forsklin group, ^^^ p < 0.001 vs 
Forskolin + IBMX group. Con:Control, HEN:HENECA, N:NaHS, Forsk:Foskolin. 
Figures taken from (Nagpure and Bian, 2014). 
 
3.3.3 NaHS targets activated AC, not A2A receptors 
RT-PCR studies (Fig 3.3A and 3.3B) demonstrated that HENECA 
stimulated expressions of mRNA of all three AC isoforms (AC1, AC3 and 
AC8). NaHS treatment effectively reduced their elevated expressions. 
Furthermore, direct enzymatic activity measurement of AC demonstrated that 




forskolin (Fig 3.3C). In addition, we explored the effect of NaHS on Aβ42 
synthesis in SH-SY5Y cells pretreated with SQ22536 (AC antagonist). We 
found that both HENECA and NaHS were unable to induce any notable effect 
on Aβ42 production (Fig 3.3D).  
NaHS treatment did not affect A2A receptors protein expression 
significantly (Fig 3.3E and 3.3F). Moreover, we noted that neither HENECA 
nor NaHS affected Aβ42 production in cells treated with ZM241385 (A2A 
receptor antagonist) (Fig 3.3G). Thus, these data indicate that NaHS 
preferentially downregulates pre-activated AC.                 





















Figure 3.3 Effect of NaHS on genes expression of neuron-specific AC isoforms and 
AC activity  
A-B: The pretreatment with NaHS (100 µM, 12 h) abolished the stimulatory effects 
of HENECA (100 nM, 24 h) on mRNA expressions of neuron-specific AC isoforms. 
C: Inhibitory effect of NaHS (100 µM) on AC activity activated by forskolin (20 
µM). D: Effect of NaHS (100 µM) on Aβ42 synthesis in SH-SY5Y cells preincubated 
with SQ 22536, AC antagonist (300 µM). E: Pretreatment with NaHS (100 µM, 12 h) 
did not affect the protein expression of A2A receptor stimulated by HENECA (100 
nM, 24 h). F: NaHS (100 µM) failed to produce any effect on Aβ42 synthesis in cells 
pre-treated with ZM 241385, an A2A receptor antagonist (50 nM). Control values 
were converted to 100%. Values are presented as means ± S.E.M, n=4-6. ## p < 0.01, 
### p < 0.001 vs Control group; +++ p < 0.001 vs Forskolin group, * p < 0.05, ** p < 
0.01 vs HENECA group. Con:Control, HEN:HENECA, N:NaHS, Forsk:Foskolin.  
Figures taken from (Nagpure and Bian, 2014) 
 
3.3.4 NaHS inhibits APP production and maturation  
 We next studied the effects of H2S on post-translational modification 
during APP processing (maturation). The maturation is a regulatory step in 
Aβ42 synthesis. During western blot, the mature (mAPP) and immature 
(imAPP) isoforms of APP can be differentiated based in their molecular 
weights. The low-molecular immature isoform (N-glycosylated) is detected at 
~110 kD and the high-molecular mature isoform (N- and O- glycosylated) at 




notably increased the amount of holoprotein APP (imAPP + mAPP, Fig 3.4A 
& 3.4B) and the ratio of mAPP to imAPP (Fig 3.4A & 3.4C). NaHS 
pretreatment notably abolished these effects. These results indicate that NaHS 
downregulates HENECA-stimulated Aβ42 production via inhibiting both 











Figure 3.4 Inhibitory effects of NaHS on APP production and maturation. 
The cell lysates were subjected to western blot analysis with antibody against N-
terminus of APP or β-actin. The effects of NaHS at 100 µM attenuated production (A 
and B) and maturation (A and C) of APP in HENECA stimulated SH-SY5Y cells. 
The ratio between mAPP to imAPP is used to quantify the maturation of APP. The 
upper and lower bands in a blot represent mAPP and imAPP isoforms respectively. β-
actin was used as a loading control. Values are presented as means ± S.E.M, n=4. ### 
p < 0.001 vs Control group; *** p < 0.001 vs HENECA group. Con:Control, 
HEN:HENECA. Figures are taken from (Nagpure and Bian, 2014). 
 
3.3.5 NaHS attenuates γ–secretase activity, not of β–secretase  
 β–secretase cleaves APP into N-terminal fragment, sAPPβ and C-
terminal fragment, C99. Therfore, the generated amount C99 is regarded as an 
activity index of β–secretase. As shown in Fig 3.5A and 3.5B, both HENECA 
and NaHS pretreatment (25-100 µM) were unable to significantly affect C99 
expression. This indicates that NaHS did not alter on β–Secretase activity in 
SH-SY5Y cells. 
Direct activity of γ-secretase in the membrane fractions of SH-SY5Y 
neuroblastoma cells was quantified as well. As evident from Fig 3.5C, 
HENECA notably stimulated activity of γ-secretase. The treatment with NaHS 
or DAPT (a γ-secretase inhibitor), markedly inhibited the effect of HENECA. 
It is also shown that NaHS pretreatment did not show any significant effect on 
γ-secretase activity (Fig 3.5C). Furthermore, DAPT downregulated Aβ42 
production HENECA-stimulated cells (Fig 3.5D). In compliance with our data 
in Fig 3.3D, the inhibition of AC with SQ22536  (AC inhibitor) did not affect 





















Figure 3.5 Different effect of NaHS on activities of β- and γ-secretases.  
A-B: NaHS (100 µM, 12 h) and HENECA (100 nM, 24 h) did not affect C99 (β-CTF) 
protein expression. The membrane fractions of SH-SY5Y cells were subjected to 
western blot analysis with primary antibody against C99 (c-terminal fragment of 
APP) or β-actin. C-D: NaHS (100 µM) mimicked the effect of DAPT (γ-secretase 
inhibitor, 1 µM, 1 hour) on HENECA (100 nM)-induced activity of γ-secretase (C) 
and Aβ42 production (D). E: NaHS (100 µM) failed to induce any change in γ-
secretase activity of SH-SY5Y cells after they were treated with SQ 22536 (AC 
antagonist, 300 µM).  Values are presented as means ± S.E.M, n=4-6. ### p < 0.001 
vs Control group; *** p < 0.001 vs HENECA group. Figures are taken from 





3.3.6 Effect of NaHS on expression of presenilins 
We then analyzed the effects of NaHS treatment on gene expressions 
of presenilins 1 (PS1) & 2 (PS2). PS1 and PS2 are the catalytic components of 
γ-secretase complex. We observed that NaHS notably downregulated 
HENECA-induced mRNA expression of PS2. On the other hand, PS1 mRNA 
levels were not significantly affected (Fig 3.6A, 3.6B and 3.6C). These data 
indicate that NaHS inhibits HENECA stimulated activation of γ-secretase. It 













Figure 3.6 NaHS inhibits mRNA expressions of presenilins 1 and 2  
NaHS pretreatment (100 µM, 12 hours) attenuated HENECA induced mRNA 
expression of PS2 and not PS1. Control values were adjusted to 100% for mRNA 
expression. Data are represented as means ± S.E.M, n=4. # p < 0.05 vs Control group; 
* p < 0.05 vs HENECA group. Con:Control, HEN:HENECA. Figures are taken from 
(Nagpure and Bian, 2014). 
 
3.4 Discussion 
Compiling epidemiological and pharmaceutical data have 
demonstrated the cogent role of adenosine signaling in modulating brain 
damage. The activation of A1A receptor subtype is more relevant in context of 
early events occurring in brain damage. It was reported that the levels of A1A 
as A2A receptors are upregulated in AD (Albasanz et al., 2008). However, it 
must be noted that the detailed autoradiography and biding analysis conducted 
in AD patients revealed reduced density of A1A receptors (Ulas et al., 1993, 
Jaarsma et al., 1991). In a more recently published study, a significantly 
reduced A1A receptor binding capacity was observed in temporal cortices and 




findings are in agreement with the reduction in A1A receptor density and 
efficiency in neurodegenerative diseases (Cunha, 2005, Gomes et al., 2011). 
On the other hand, the inhibition of A2A receptors is crucial in relation 
of the latter events. It has also been reported that efficiency of A2A receptors 
remains unaffected or increases when they are subjected to chronic harmful 
insults (Cunha, 2005). Arendash et al have published that A2A receptor 
expression is notably elevated in the Swedish mutation transgenic mice 
(Arendash et al., 2006). Multiple studies conducted in various animal models 
of AD have demonstrated that caffeine by acting as a non-selective antagonist 
of adenosine receptors improves memory performance in animals (Takahashi 
et al., 2008). It was also found that adenosine A2A receptors (and not A1A 
receptors) inhibition imitated the neuroprotective effect of caffeine against 
neurotoxicity induced by Aβ (Dall'lgna et al., 2003) and prevented the 
development of synaptotoxicity responsible for memory dysfunction in vivo 
(Canas et al., 2009). Thus, A2A receptor signaling antagonization is 
considered as a major potential therapeutic strategy for drug development 
against chronic CNS diseases like AD (Stone, 2002, Cunha, 2005).    
Current study was aimed to explore the effect of H2S on HENECA-
induced Aβ42 production in APPswe transfected SH-SY5Y neuroblastoma 
cells, an accepted cell model of AD. As established in our study, elevated 
Aβ42 production was result of specific A2A receptor stimulation with 
HENECA. Fundamentally, this is congruous with the findings of a study done 
elsewhere (Arendash et al., 2006) where elevated productions of Aβ40 and 
Aβ42 were observed in AD transgenic mice and APPswe transfected N2a 




Aβ40 and Aβ42 forms are pathological in nature. But, prevailing Aβ42 (42 
amino-acid long) peptide is quickly collective and hence more harmful (Klein 
et al., 1999). We demonstrated that NaHS downregulated HENECA-induced 
release of Aβ42 from SH-SY5Y cells in a concentration-dependent manner.  
As adenosine A2A receptors are positively linked to AC, their 
stimulation culminates into increased intracellular cAMP levels. Exhaustive 
studies in both cell and animal models of AD have shown that cAMP-
dependent signaling pathway is crucial in processing of APP. It was reported 
that activated cAMP signaling could stimulate APP gene expression, 
increasing the intracellular production of APP holoprotein (Lee et al., 1997). 
The elevation of cAMP level caused increase in APP protein expression and 
processing in neuronal cells (Kumar et al., 1999). When PKA antagonist was 
directly administered in the brains of AD transgenic mice, it inhibited Aβ 
synthesis in the hippocampus (Su et al., 2003). A previous study conducted by 
our group has reported that H2S exerts an inhibitory effect on intracellular 
cAMP production in different cell types like JG cells of kidney, vascular 
smooth myocytes and cardiomyocytes (Lim et al., 2008, Yong et al., 2008, Lu 
et al., 2012). On the basis of these accounts, it was rational to hypothesize the 
involvement of cAMP signaling pathway in the observed inhibitory effects of 
H2S.  
We detected the increase in the intracellular cAMP level by activating 
A2A adenosine receptors. The elevation was concurrent with the stimulation 
in production of Aβ42. We found the similar results when cAMP was raised 
either by stimulation of AC with forskolin or inhibition of phosphodiesterase 




synthesis in conditions indicated above. There also exist some conflicting 
reports showing the elevation in intracellular cAMP level after NaHS 
treatment (Kimura, 2000). It appears that there could be number of variables 
determining the effect of H2S on intracellular cAMP levels in different cell 
types.   The treatment duration with and final H2S concentration could be key 
factors. Furthermore, the variable existence of different isoforms of AC and/or 
PDE; the presence of other intracellular secondary signaling pathways 
simultaneously in a cell can change the final effect. Human possess nine 
isoforms of AC (AC 1-9), of which 3 isoforms, namely AC1, AC3 and AC8 
are solely expressed in neurons (Defer et al., 2000).  We found that H2S 
downregulated the expressions of all 3 AC isoforms in HENECA stimulated 
cells. Many reports have come from a recent study of our group where NaHS 
lowered upregulated protein and mRNA expressions of AC isoforms and 
cAMP synthesis in selective µ-opioid receptor agonist treated SH-SY5Y cells 
and the striatum of morphine-dependent mice. Moreover, H2S downregulated 
the increased AC activity in HENECA stimulated cells (Yang et al., 2013).  
cAMP targets CREB transcription factor as a primary downstream 
target. We observed that NaHS pretreatment prevented HENECA stimulated 
CREB phosphorylation. Moreover, the results using specific inhibitor of 
PKA/CREB bolstered our hypothesis as it also abolished Aβ42 synthesis. 
Furthermore, AC inhibition did not yield any notable change in Aβ42 
production. In contrast to AC isoforms, H2S did not show any direct 
suppressing effect on protein expression of A2A receptors. Additionally, 
neither HENECA nor H2S induced any notable change in Aβ42 levels in the 




suppresses activity and expression of only AC, thus inhibiting its downstream 
pathway. 
The production of Aβ is closely controlled by post-translational 
modifications of APP and the proteolytic activities of secretases. The 
immature isoform of APP (imAPP) is N-glycosylated and is mainly found in 
endoplasmic reticulum (ER). The process of maturation takes place in Golgi 
complex by its O-glycosylation forming mature APP (mAPP). The 
reinternalisation of APP in endosomes is a common phenomenon after its 
insertion into plasma membrane, culminating into synthesis of Aβ (Xia et al., 
1997). The trafficking and maturation process of APP may be disrupted 
resulting into AD pathogenesis (Haass et al., 1995, Xia et al., 1997).  In an 
earlier study, Su et al showed that inhibition of PKA results into accumulation 
of imAPP leading to lowered Aβ42 production (Su et al., 2003). Here in this 
study, we observed that H2S notably abrogated the effect of HENECA on 
mAPP/imAPP ratio. Moreover, H2S is known to arrest the activity of 
sarcoplasmic/endoplasmic reticulum calcium ATPase pump (SERCA) (Chen 
et al., 2012). These data indicate that H2S possibly alters APP metabolism at 
the level of ER. It is also feasible that H2S interrupts mAPP reinternalization 
into endosomes. Although the lowered Aβ42 production can be explained on 
the basis of inhibition of APP maturation to a certain extent, the definite 
underlying mechanism is still ambiguous and warrants further exploration.  
An aspartyl protease, BACE1 is the key rate-limiting enzyme in the 
process of Aβ production. Our results showed that the expression of C99 (β –
CTF) was unaltered, suggesting that H2S did not modify β –secretase activity. 




expression and Aβ42 generation in unstimulated rat pheochromocytoma PC12 
cells (Zhang et al., 2011). The supposed disparities between these reports can 
be clarified based on variations in experimental parameters such as cell line 
used, transfection with Swedish mutation and duration of NaHS pretreatment.  
Nonetheless, H2S inhibits the activity of γ-secretase affecting the 
proteolytic processing of APP. γ-secretase is a high-molecular weight protein 
complex composed of four known units: presenilins (PS1 and PS2), presenilin 
enhancer 2 (PEN-2), anterior pharynx defective 1 (APH-1) and nicastrin (De 
Strooper, 2003). The involvement of γ-secretase complex in AD pathology 
became indisputable with the recognition of PS1 and PS2 as major 
pathological genes in cases of familial AD (St George-Hyslop, 2000). In the 
present study, we report that increased cAMP level and CREB 
phosphorylation by stimulation of adenosine A2A receptors prompts in 
enhanced γ-secretase activity. We observed that H2S inhibited HENECA-
stimulated γ-secretase activity. Additionally, we found that H2S notably 
downregulated the HENECA-stimulated mRNA expression of PS2, which is 
the major catalytic subunit of γ-secretase complex. Human neural cells express 
two independent regulatory systems controlling PS1 and PS2 genes 
expressions (Satoh and Kuroda, 1999). This can explain the specific effect of 
H2S on PS2 mRNA expression and not PS1’s. 
Collectively, the present study indicates that H2S may have a beneficial 
therapeutic role in AD treatment as it lowers HENECA-induced Aβ42 
production by inhibiting APP maturation and attenuating γ-secretase by a 




H2S on adenosine A2A receptor signal transduction pathway can be studied 











Figure 3.7 Schematic diagram depicting the inhibitory effect of H2S on HENECA 
induced Aβ production in APPswe transfected SH-SY5Y cells 
APP is a transmembrane protein which goes through post-translational modifications 
like glycosylation during its transfer via intracellular secretory pathway. The mature 
form of APP finally yields Aβ when it is acted upon by β- and γ-secretases. 
HENECA, an A2A receptor agonist, induces Aβ42 production in SH-SY5Y 
neuroblastoma cells via cAMP/PKA/CREB signaling pathway. It elevates both 
synthesis and maturation of APP, upregulating total APP production. It also 
stimulates γ-secretase activity on C99 (β-CTF) resulting in Aβ production. H2S not 
only interrupts APP maturation, but also inhibits the synthesis of APP holoprotein. 
By attenuating AC (and following cAMP production), H2S also blocks γ-secretase 
activity. It eventually leads to lowered Aβ production. The figure has been taken from 


























4 Hydrogen sulfide repairs impaired glutamate uptake in A2A 














Glutamate is the primary and most plentiful excitatory neurotransmitter 
in CNS, regulating a large share of synaptic transmission in the mammalian 
brain (Fonnum, 1984). Although it is crucial for learning, memory and 
cognition (Headley and Grillner, 1990); its chronic and excessive 
accumulation causes excitotoxicity (Greenamyre et al., 1988). The 
excitotoxicity has been implicated in the pathogenesis of many 
neurodegenerative diseases (Benarroch, 2010) including AD (Hynd et al., 
2004). As glutamate remains unmetabolised in the extracellular area of 
synapses, glutamate clearance/ reuptake is primarily maintained by astrocytic 
glutamate transporters, the EAAT1 (human homologue)/ GLAST (rodent 
homologue) and EAAT2/ GLT-1 (Danbolt, 2001).  
The altered glutamate transport, possibly resulting from changes in the 
glutamate transporters expressions has been inculpated in AD pathology. The 
studies done in cerebral cortices of AD patients revealed a decreased number 
of high-affinity glutamate uptake sites in many areas of cortex (Scott et al., 
1995, Cross et al., 1987). Furthermore, a decreased protein expressions of 
EAAT1 and EAAT2 were detected in the neocortices of AD transgenic mouse 
model (Masliah et al., 2000). A comparatively recent study done by Scott et al 
implicated abnormal glutamate transporter expression as one of the 
mechanisms involved in neurodegeneration of AD (Scott et al., 2002).  
Adenosine is a classical and ubiquitous modulator of synaptic 
neurotransmission and it acts via four GPCRs i.e. A1A, A2A, A2B and A3. 




hand, A2A and A2B subtypes are coupled to Gs protein, stimulating AC 
(Fredholm et al., 2005). Adenosine modulates excitatory neurotransmission by 
delicately coordinating signaling through inhibitory A1A and excitatory A2A 
receptors subtypes (Gomes et al., 2011). As mentioned in the introduction of 
this thesis, these two receptors have always been considered as the potential 
drug targets against major neurodegenerative diseases. The facilitation of A1A 
receptor signaling and/or blocking of A2A receptor signaling are the two most 
thought upon strategies to check the progress of neuronal degeneration 
(Cunha, 2005). Adenosine receptors are also present in astrocytes where they 
modulate many important functions including cell reproduction and death, 
glucose metabolism, release of neurotrophic proteins & anti/pro-inflammatory 
interleukins and astrogliosis (Boison et al., 2010, Dare et al., 2007). 
In the previous chapter, an inhibitory effect of H2S was demonstrated 
in A2A receptor agonist-stimulated SH-SY5Y neuroblastoma cells transfected 
with Swedish mutation of APP. In this chapter, few experiments were 
performed to investigate the possible effects of H2S on glutamate transporters 
and glutamate uptake in primary astrocyte culture stimulated by A2A receptor 
agonist, HENECA. We also attempted to find the underlying signaling 
mechanism for the observed effect.  
 
4.2 Material and Methods 
4.2.1 Chemicals 





4.2.2 Primary astrocyte culture 
 Please refer to section 2.4 
4.2.3 Intracellular cAMP Assay 
 Please refer to section 2.6 
4.2.4 Glutamate uptake assay 
 Please refer to section 2.16 
4.2.5 Statistical analysis 
 Please refer to section 2.19 
 
4.3 Results 
Figure 4.3.1 The effect of NaHS on expression of glutamate transporter in 
A2A adenosine receptor agonist stimulated astrocytes  
 The expression level of GLAST (glutamate aspartate transporter), the 
primary glutamate transporter in rodent astrocytes, affects the uptake of 
glutamate by astrocytes. To investigate the possible protective effect of NaHS 
on glutamate transporter, we analyzed the changes in its expression by western 
blot. As shown in Fig 4.1A and 4.1B, A2A receptor stimulation by its specific 
agonist, HENECA (100 nM, 6 hours) downregulated the expression level of 













Figure 4.1 Effect of NaHS on GLAST protein expression  
A-B: Representative gels (A) and histogram (B) demonstrating the effect of 
pretreatment with NaHS (100 µM) on the protein expression of GLAST receptor in 
primary astrocytes treated with HENECA (100 nM). Control values were adjusted to 
100%. Data are given as means ± S.E.M, n=4. ## p < 0.01 vs Con group; * p < 0.05 vs 
HENECA group. HEN:HENECA. 
 
4.3.1 The effect of NaHS on glutamate uptake in A2A adenosine 
receptor agonist stimulated astrocytes 
 The glutamate uptake was also quantified using commercially 
available gluatamate assay kit provided by Abcam. As indicated in Fig 4.2, 
treatment with HENECA (100 nM) for 6 hours significantly lowered the 
glutamate uptake in primary rat astrocytes. NaHS (100 µM) notably reversed 
HENECA-induced impairment of glutamate uptake. This result demonstrates 
Cont HEN 
   HEN 






the restorative and protective effect of H2S against HENECA-induced 
impairment of glutamate uptake. 
A 
 
Figure 4.2 Effect of NaHS on glutamate uptake 
A: NaHS (100 µM) reversed the effect of HENECA on glutamate uptake. The 
intracellular glutamate levels in astrocytes were quantified by commercially available 
kit. Control values were converted to 100%. Values are presented as means ± S.E.M, 
n=6. ## p < 0.01 vs Control group, * p < 0.05 vs HENECA group. 
 
4.3.2 The involvement of cAMP signaling pathway in the protective 
effect of NaHS on HENECA-stimulated astrocytes 
In an attempt to find the underlying signaling mechanism for the 
effects of NaHS, we analyzed the involvement of cAMP signaling pathway. 
As shown in Fig 4.3, HENECA at 100 nM concentration elevated intracellular 
cAMP levels in astrocytes. NaHS (100 µM) concentration-dependently 
abolished the intracellular cAMP levels augmented by HENECA. It should be 







Figure 4.3 Effect of NaHS on glutamate uptake in HENECA-stimulated astrocytes 
involves cAMP signaling pathway 
A: Effect of NaHS (100 µM) on HENECA (100 nM)-stimulated cAMP production. 
The intracellular cAMP levels were quantified by sandwich ELISA kits. Values are 




In the hippocampal slices of Guiana pig, adenosine was reported to 
facilitate neurotransmission. The probable mechanism behind this facilitatory 
action was the elevated release of glutamate from activated presynaptic 
neurons. However, scientists soon found out that adenosine stimulated 
glutamate is released even in non-excitable conditions. It indicated the 
possibility of another source of glutamate i.e. release from glial cells. In 
support of this hypothesis, Li et al reported that adenosine stimulates 
glutamate efflux from glial cells via A2A adenosine receptors (Li et al., 2001). 
Furthermore, in an important study conducted by Pintor et al, they found that 




of the uptake system by glutamate uptake inhibitors (Pintor et al., 2004). 
Matos and group also showed that activated adenosine A2A receptors in 
astrocytes regulate the glutamate uptake. The regulation probably occurs 
through two different mechanisms depending upon the duration of activation 
of A2A receptors. The persistent activation of A2A receptors activates 
secondary cAMP dependent pathway which inhibits the expression of GLAST 
and GLT-1, thus lowering the densities and activities of both the transporters. 
On the other hand, acute A2A receptor activation abrogates the activity of 
glutamate transporters through a mechanism which is still under investigation 
(Matos et al., 2012).  
Based on the results of above-mentioned studies, we used HENECA, a 
specific agonist of A2A receptors to study the protective effect of NaHS 
against excitotoxicity. In neonatal or adult astrocytic cell, GLT-1 glutamate 
transporters are hardly detected, possibly due to the lack of inducible neuronal 
factors which stimulate expression of GLT-1. Thus, GLAST are considered as 
the major type of glutamate transporters expressed in primary astrocytes 
(Kondo et al., 1995). In our study, we found that HENECA decreased the 
protein expression of GLAST. NaHS pretreatment reversed the effect of 
HENECA, thereby elevating its GLAST expression. Additionally, incubation 
with HENECA lowered the intracellular levels of glutamate suggesting the 
glutamate uptake was also decreased.  H2S elevated the glutamate uptake by 
astrocytes. Li at el suggested that glutamate efflux by glial cells might be 
regulated by a cAMP dependent protein kinase pathway (Li et al., 2001). As 
mentioned above, Matos and group also found out that long-term activation of 




activity of GLAST transporters (Matos et al., 2012). In our study, we found 
out that H2S inhibited the elevated intracellular cAMP levels. We believe that 
inhibition of cAMP dependent secondary pathway holds the key for the 
restorative effect of H2S on glutamate uptake. 
A2A adenosine receptors have crucial function of modulating 
glutamate uptake by astrocytes, which is one of the most important roles of 
astrocytes in maintaining synaptic neurotransmission. The activity of 
glutamate transporters is very important in pathological CNS conditions. A2A 
receptors, by controlling glutamate uptake, possess a potential drug target 
against excitotoxicity (Matos et al., 2012). H2S, by attenuating A2A adenosine 





















5 Hydrogen sulfide inhibits the Aβ synthesis and neuroinflammation in 
extracellular ATP-stimulated BV-2 microglia cells via inhibition of 
















In one of the previous chapters, an anti-amyloidogenic role of H2S was 
demonstrated in A2A receptor agonist stimulated SH-SY5Y neuroblastoma 
cells transfected with Swedish mutation of APP. In this chapter, a series of 
experiments was performed in microglia that are resident macrophages of the 
brain and thus contribute to active immune defense in CNS. We tested 
whether H2S exerted anti-inflammatory effects in BV2 microglia cells 
inhibiting the production of Aβ. To study the possible underlying mechanisms, 
we analyzed effects of H2S on NF-κB and involvement of STAT3 and 
cathepsin S in the observed effects.  
AD is a major neurodegenerative disease, generally affecting people 
with age more than over 60 years. It is characterized by progressive cognitive 
decline and dementia (Maccioni et al., 2014). Researchers and clinicians 
across the globe have identified numerous therapeutic targets to treat AD or 
alleviate its symptoms. There are convincing epidemiological evidences that 
long standing anti-inflammatory drug therapy has useful effects against AD 
risk, symptomatic severity and overall disease progression (McGeer et al., 
1996, Rich et al., 1995, Stewart et al., 1997).  
Numerous studies performed in cell models (McGeer et al., 1996), 
animal models (Akiyama et al., 2000) and post-mortem patients (Haga et al., 
1989, Choi et al., 2013) of AD suggest that neuroinflammation plays an 
indisputable role in its pathogenesis and progression. Activated microglia are 
recognized as the key cellular regulators of innate immune system in adult 




mechanical insult. Extracellular ATP, a strong activator of microglia, is 
copiously released in the brain from damaged neurons and astrocytes, 
activated platelets, T-cells and endothelial cells following episodes of trauma, 
hypoxia, stress and any other inflammatory reaction (Volonte et al., 2003). 
Once activated, microglia release various cytokines, chemokines and 
superoxide radicals (Kalaria, 1999)  which contribute to neuronal damage 
continuing the vicious cycle of neurodegeneration. 
As discussed earlier in this thesis, Aβ, the biggest culprit of amyloid 
pathology of AD, is derived from sequential proteolytic cleavage of APP by β- 
and γ-secretases. The expression of APP is known to be stimulated by nitric 
oxide (NO), interleukin 1 (IL-1) and TNF-α (McGeer and McGeer, 2003). 
These pro-inflammatory cytokines also upregulate activity of β-secretase 
(Rossner et al., 2006). TNF-α and interferon gamma (IFN-γ) have been 
reported to elevate Aβ production in the brains of Swedish mutant APP 
transgenic mice (Yamamoto et al., 2007). The initialization of subsequent 
intracellular cascades might contribute to amyloid plaque generation (Sheng et 
al., 2003). Reactive glial cells have been believed to play an important role in 
amyloid plaque evolution i.e. conversion of plaques from diffuse to neuritic 
variety (Mackenzie et al., 1995, Eikelenboom et al., 1994).  
Various transcription factors play critically important roles in AD 
pathology and other chronic neurodegenerative diseases. Nuclear factor-kappa 
B (NF-κB) is known to stimulate the expression of many inflammatory 
mediators including cytokines, inducible nitric oxide synthase (iNOS) and 
cyclooxygenase-2 (COX-2). Its activation was found to upregulate BACE-1 




and activator of transcription 3 (STAT3) has also been demonstrated to be 
involved in neuronal differentiation, inflammation and Aβ pathology (Wen et 
al., 2014). Along with the transcription factors, lysosome proteases play 
crucial roles in neuronal development, synaptic plasticity and 
neurodegeneration (Chen et al., 2008, Haque et al., 2008). Cathepsin S, a 
lysosomal cysteine proteases, is expressed predominantly in the microglia 
(Petanceska et al., 1996). Moreover, many studies suggest that it has a 
definitive role in AD pathology (Lemere et al., 1995). 
The emergence of the understanding of H2S being an important 
modulator of multiple physiological functions in various body systems has 
changed the opinion of scientific community (Bhatia et al., 2005, Liu et al., 
2012, Lee et al., 2006b). It is now identified as an endogenous gasotransmitter 
along with nitric oxide and carbon monoxide, which works at micromolar 
levels in mammalian cells (Wang, 2002a). It is well known that H2S protects 
neurons against hypoxic insult (Tay et al., 2010); glial cells against cell 
toxicity caused by Aβ (Liu and Bian, 2010) and inflammation induced by 
bacterial lipopolysaccarides (Hu et al., 2007a). In a recent finding, H2S was 
found to improve impairment in spatial memory along with reduction in Aβ 
generation in AD transgenic mice (He et al., 2014).  However, whether H2S 
can produce protective effects against neuroinflammation and subsequent 
amyloidogenesis induced by extracellular ATP has not been explored. The 
current study was thus designed to test the effect of H2S on production of 





5.2 Materials and Methods 
5.2.1 Chemicals 
 Please refer to section 2.1 
5.2.2 Cell Culture and Treatments 
Please refer to section 2.2 
5.2.3 Constructs and mutagenesis 
 Please refer to section 2.3 
5.2.4 Cell Viability Assay 
 Please refer to section 2.5 
5.2.5 Intracellular cAMP Assay 
 Please refer to section 2.6 
5.2.6 γ-secretase (Fluorogenic Substrate) Assay 
 Please refer to section 2.8 
5.2.7 ELISA for Aβ42 
 Please refer to section 2.9 
5.2.8 Reactive Oxygen Species (ROS) Measurement 
 Please refer to section 2.10 
5.2.9 Nitric oxide (NO) Measurement 




5.2.10 DNA binding activity assay 
Please refer to section 2.13 
5.2.11 Cathepsin S activity assay 
 Please refer to section 2.14 
5.2.12 S-sulfhydration assay  
 Please refer to section 2.15 
5.2.13 Western Blot Assay 
Please refer to section 2.18 
5.2.14 Statistical Analysis 
 Please refer to section 2.19 
 
5.3 Results 
5.3.1 Effect of NaHS on ATP-induced oxidative stress and inflammation 
in BV-2 microglial cells 
We first investigated the effects of NaHS and ATP on BV-2 microglial 
cells viability. It was found that pretreatment with NaHS at a concentration 
range (10-200 µM) for 6 h did not significantly alter cell viability (Fig 5.1A). 
Stimulation of BV-2 microglial cells with different concentrations of ATP 
(0.1-5 mM, 3 h) in the presence and absence of NaHS also failed to affect cell 
viability (Fig 5.1B). For this reason, 100 µM of NaHS and 1 mM of ATP were 




As shown in Fig 1C & 1D, treatment with ATP (1 mM, 3 h) 
significantly elevated the levels of ROS and NO. Pretreatment of BV-2 cells 
with NaHS (100 µM, 6 h) significantly attenuated the ATP-induced ROS (Fig 
5.1C) and NO (Fig 5.1D) production. Additionally, the secretion of TNF-α and 
IL-1β were measured in culture medium as an indicator of BV-2 microglia cell 
activation. We found that pretreatment with NaHS (100 µM) for 6 h also 
reduced ATP-induced TNF-α (Fig 5.1E) and IL-1β (Fig 5.1F) generation in a 
significant manner. Notably, NaHS alone did not produce any significant 




















Figure 5.1 Effect of NaHS on ATP-induced oxidative stress and inflammation in BV-
2 microglial cells 
A: MTT assay showing the effect of NaHS alone at 10-200 µM on cell viability of 
BV-2 microglia cells.  B: MTT assay showing the effect of ATP on cell viability of 
BV-2 microglia cells in presence or absence of NaHS. C: Effect of NaHS (100 µM, 6 
h) on ROS production in BV-2 microglia cells stimulated by ATP (1 mM, 3 h). D:  
Effect of NaHS (100 µM, 6 h) on ATP (1 mM, 3 h)-stimulated nitrite upregulation. E-
F: Effects of NaHS (100 µM, 6 h) on TNF-α (E) and IL-1β (F) production in cells 
treated with ATP (1 mM, 3 h). The intracellular ROS levels were determined by 
analyzing DCF-fluorescence. The nitrite measurement, representative of NO 
production, was determined by Griess reagent kit. Control values were adjusted to 
100%. Data are given as means ± S.E.M, n=6.  ## p < 0.01 ### p < 0.001 vs Con group, 
*p < 0.05,** p < 0.01, *** p < 0.001 vs ATP group. Con: Control. 
 
5.3.2 Effect of NaHS on ATP-induced iNOS and COX-2 expression in 
microglial cells  
The increased expression of iNOS and COX-2 is a hallmark feature of 
neuroinflammation (Brown and Neher, 2010, Minghetti, 2004). We performed 
Western blot analysis to determine whether inhibition of NO production by 
NaHS was associated with the downregulated protein levels of iNOS and 
COX-2. The resultant data showed that treatment with ATP significantly 
increased iNOS and COX-2 protein expression compared to the un-stimulated 
cells. NaHS markedly inhibited iNOS (Fig 5.2A) and COX-2 (Fig 5.2B) 















Figure 5.2 Effect of NaHS on protein expression of iNOS and COX-2  
A: Representative gels and histogram demonstrating that pretreatment with NaHS 
(100 µM, 6 h) attenuated the effects of ATP (1 mM, 3 h) on protein expressions of 
iNOS. B: Representative gels and histogram demonstrating that NaHS pretreatment 
(100 µM, 6 h) attenuated the effects of ATP (1 mM, 3 h) on protein expressions of 
COX-2. Control values were adjusted to 100%. Data are given as means ±S.E.M, 
n=4. ### p < 0.001 vs Con group; ** p < 0.01 vs ATP group. Con: Control. 
 
5.3.3 Effect of NaHS on DNA binding and transcriptional activities of 
NF-κB in ATP-stimulated microglial cells 
NF-κB, a protein complex that controls transcription of DNA, 
modulates the expressions of iNOS and COX-2 at the transcriptional level. 
This results in production of various pro-inflammatory factors. The 
involvement of NF-κB in the anti-inflammatory effects of NaHS was therefore 
examined.  To investigate whether NaHS can also inhibit NF-κB DNA-
binding activity, BV-2 microglia were pretreated with NaHS before ATP 
stimulation. Nuclear extracts from treated cells were taken and examined for 
NF-κB DNA-binding by a commercially available NF-κB transcription factor 
assay kit. As shown in Fig 5.3A, ATP-induced rise in NF-κB binding activity 
in cultured microglia was inhibited by pretreatment with NaHS at 25-100 µM 
in a concentration-dependent manner, while NaHS alone at 100 µM had no 
significant effect. 
To demonstrate the underlying mechanism of above-mentioned 
observation, we analyzed the nuclear translocation of p65 and degradation of 
IκBα. As shown in Fig 5.3B, NaHS prevented ATP-induced p65 translocation 




IκBα was also inhibited by NaHS (Fig 5.3C). These results indicate the NaHS 
inhibits ATP-induced NF-κB activation via blocking p65 translocation into the 



















Figure 5.3 Effect of NaHS on DNA binding and transcriptional activities of NF-κB  
A: Concentration dependent effect of NaHS (25-100 µM) on DNA binding activity of 
NFκB. B: Representative gels and histogram demonstrating that NaHS pretreatment 
(100 µM, 6 h) attenuated the effects of ATP (1 mM, 3 h) on nuclear translocation of 
p65. C: Representative gels and histogram demonstrating the effect of pretreatment 
with NaHS (100 µM, 6 h) attenuated the effects of ATP (1 mM, 3 h) on protein 
expression of phosphorylated IκBα. Control values were adjusted to 100%. Data are 
given as means ± S.E.M, n=4-6. ## p < 0.01, ### p < 0.001 vs Con group; * p < 0.05, ** 
p < 0.01 vs ATP group. Con: Control. 
 
5.3.4 Effect of NaHS on ATP-induced Aβ42 production in microglial 
cells 
We also investigated the effect of NaHS on Aβ42 formation in BV-2 
microglia. As shown in Fig 5.4A, NaHS significantly inhibited the ATP-
stimulated Aβ42 production. To study the mechanism, we measured APP 
expression, β- and γ-secretases enzymes activities (Fig 5.4B-4D).  ATP 







treatment upregulated protein expression of APP (a precursor protein of Aβ, 
Fig 5.4B), C99 (an index of β- secretase activity, Fig 5.4C) and activity of γ-
secretase (Fig 5.4D) in BV-2 cells. These effects were largely attenuated by 
pretreatment with NaHS, suggesting that NaHS inhibits ATP-stimulated Aβ42 












Figure 5.4 Effect of NaHS on ATP-induced Aβ42 production 
A: Dose-dependent effect of NaHS (25-100 µM, 6 h) on Aβ42 formation in the 
presence and absence of ATP (1 mM, 3 h). B: Representative gel and quantitative 
analysis showing the effects of NaHS (100 µM, 6 h) on ATP (1 mM, 3 h) stimulated 
expression of APP. C: Representative gel and quantitative analysis showing effects of 
NaHS (100 µM, 6 h) and ATP (1 mM, 3 h) C99 expression in BV-2 cells. D: Dose-
dependent effect of NaHS (25-100 µM, 6 h) on γ-secretase activity in the presence 
and absence of ATP (1 mM, 3 h). Control values were adjusted to 100%. Data are 
given as means ± S.E.M, n=4-6. #p < 0.05, ## p < 0.01 ,### p < 0.001 vs Con group; * p 





5.3.5 Effect of NaHS on STAT3 activity in microglial cells 
STAT3 along with NF-κB influences many factors contributing to 
neuroinflammation and Aβ production. We found in the present study, ATP 
stimulated phosphorylation (activation) of STAT3 while NaHS pretreatment 
abolished the effect (Fig 5.5A). To further elaborate the involvement of 
STAT3, we employed SC203282, a selective inhibitor of STAT3. As shown in 
Fig 5.5B & 5.5C, SC203282 mimicked the inhibitory effect of NaHS on the 
production of Aβ42 (Fig 5.5B) and NF-κB DNA-binding activity (Fig 5.5C) in 
ATP-stimulated cells. This finding suggests that NaHS targets STAT3 to 













Figure 5.5 Effect of NaHS on STAT3 activity  
A: Representative gels  and histogram demonstrating the effect of pretreatment with 
NaHS (100 µM, 6 h) attenuated the effects of ATP (1 mM, 3 h) on protein expression 
of phosphorylated STAT3 . B-C: Effect of NaHS (100 µM) and STAT3 antagonist, 
SC203282 on Aβ42 production (B) and NFκB DNA binding activity (C) in ATP-
stimulated BV-2 cells.  Control values were adjusted to 100%. Data are given as 
means ± S.E.M, n=4-6. # p < 0.05, ## p < 0.01, ### p < 0.001 vs Con group; * p < 0.05 






5.3.6 Involvement of cathepsin S in the observed effects of NaHS on 
ATP-induced neuroinflammation and Aβ production 
  In an attempt to test the involvement of cathepsin S, a lysosomal 
protease, in the effects of NaHS in BV-2 microglia, we directly measured the 
activity of cathepsin S in the cells treated with ATP. As shown in Fig 5.6A, 
NaHS pretreatment abolished ATP-stimulated cathepsin S activity. 
Interestingly, blockade of STAT3 with SC203282 produced a similar effect 
(Fig 5.6A). Moreover, both NaHS and SC203282 attenuated the ATP-
enhanced cathepsin S protein expression (Fig 5.6B).  
 To further confirm the role of cathepsin S in ATP-stimulated-effects in 
BV-2 microglia, a specific cathepsin S inhibitor was used. As shown in Fig 
5.6C, both cathepsin S inhibitor and NaHS produced comparable inhibitory 
effect on ATP-stimulated cathepsin S activity (Fig 5.6C). Moreover, we noted 
that neither DNA binding activity (Fig 5.6D) nor Aβ42 production (Fig 5.6E) 
was affected by ATP, NaHS or SC203282 when BV-2 cells were preincubated 
with the specific cathepsin S inhibitor. Thus, these data indicate that cathepsin 
S is important to ATP-induced Aβ42 over-production and neuroinflammation 
and also an important target for H2S treatment. 
Cathepsin S along with other members of cysteine cathepsin family has 
highly conserved single cysteine residue at position 25 (Cys-25) in the active 
site (McGrath et al., 1998, Turk et al., 2012). Our results demonstrated that 
NaHS at 100  µM induced cathepsin S sulfhydration (Fig 5.6F). Mutation of 
the conserved Cys-25 to serine (C25S) abolished H2S-induced sulfhydration of 



























Figure 5.6 Involvement of cathepsin S 
A: Effect of NaHS (100 µM) and STAT3 antagonist, SC203282 on cathepsin S 
activity in ATP-stimulated BV-2 cells. B: Representative gels and histogram 
demonstrating the effect of NaHS pretreatment (100 µM, 6 h) inhibiting the effects of 
ATP (1 mM, 3 h) on protein expression of cathepsin S. C: Effect of NaHS (100 µM) 
and cathepsin S inhibitor on cathepsin S activity in ATP-stimulated BV-2 cells. D: 
Effect of NaHS (100 µM), and STAT3 antagonist, SC203282 on DNA binding 
activity of NFκB in BV-2 cells pre-treated with cathepsin S inhibitor. E: Effect of 
NaHS (100 µM), and STAT3 antagonist, SC203282 on Aβ42 formation in BV-2 cells 
pre-treated with cathepsin S inhibitor. F: Representative gels and analytical histogram 
demonstrating NaHS induced cathepsin S sulfhydration in HEK293 cells. C25S 
abolished H2S-induced cathepsin S sulfhydration in HEK293 cells. On the other hand, 
C216S did not affect H2S-induced cathepsin S sulfhydration in HEK293 cells. Cells 
were transfected with either pcDNA3-cathepsin S (WT-HEK), pcDNA3-cathepsin S-
C25S cDNAs (C25S-HEK) or pcDNA3-cathepsin S-C216S cDNAs (C216S-HEK). 
Control values were adjusted to 100%. Data are given as means ± S.E.M, n=4-6. # p < 
0.05, ## p < 0.01 vs Con group; * p < 0.05 vs ATP group. Con: Control, SC: 






 Accumulating evidence in basic and clinical studies demonstrate that 
neuroinflammatory processes are associated with AD pathology. There is a 
positive correlation between neuroinflammatory reactions and Aβ production. 
There are many studies reporting that anti-inflammatory agents prevent AD 
pathology in many in vitro and in vivo studies. Earlier it was reported that NO-
releasing NSAID reduces microglial activation and Aβ deposition in APP/PS1 
AD transgenic mice (Jantzen et al., 2002).  Anti-inflammatory drug ibuprofen 
has been demonstrated to suppress various aspects of AD pathology, including 
inflammation and Aβ deposition in a mouse model for AD (Lim et al., 2000). 
In a study done on Tg2576 mice, Sung et al showed that chronic 
administration of anti-inflammatory drug indomethacin resulted in significant 
reduction in amyloid burden, ultimately lowering the AD pathology 
(Smalheiser and Swanson, 1996, Sung et al., 2004). Previous studies have 
reported that ATP can accelerate formation and deposition of Aβ fibrils 
(Exley, 1997, Exley and Korchazhkina, 2001).  Our data show that 
extracellular ATP induced neuroinflammation, as evident from increased 
protein expressions of COX-2 and iNOS, had triggered the expression of APP 
in BV-2 microglia. We observed that H2S not only inhibited the elevated 
expressions of COX-2 and iNOS, it also lowered the oxidative stress by 
blocking the production of NO and ROS. Yamamoto et al reported that the 
proinflammatory cytokines are directly associated with AD pathology by 
demonstrating the stimulatory effects of TNF-α and IFN-γ on Aβ deposition 
(Yamamoto et al., 2007). In the present study, we found that H2S pretreatment 




cells. Our study indicates that H2S possess anti-inflammatory properties 
against ATP-induced neuroinflammation, which culminates into lowered 
production of Aβ.  
The mechanisms by which H2S affects Aβ production are likely to be 
complex and diverse. APP undergoes a sequential proteolysis, first by β-
secretase generating plasma membrane-attached small fragment C99. The 
second proteolysis involves action of γ-secretase on C99 to generate Aβ42. 
Thus in the next stage of experiments, we analyzed the result of H2S 
pretreatment with or without ATP, on β- and γ- secretase activities. H2S 
abolished ATP-induced β- and γ-secretase activities, consonant with its 
previous effect on overall Aβ42 generation.  It has been reported that the 
major proinflammatory cytokines like TNF-α, IL-1β and IL-6 stimulated 
signaling mechanisms to elevate APP gene expression (Hirose et al., 1994) 
and Aβ production (Liao et al., 2004). In order to seek the molecular 
mechanism behind amyloidogenic effect of inflammatory insults, Cho and 
colleagues observed the modulatory effect of proinflammatory cytokine 
stimulation on the mRNA levels, expression, and subsequently β-secretase 
activity in neural cells (Cho et al., 2007). Rogers et al identified a novel IL-1-
responsive and basal translational enhancer in the 5′-UTR of the APP gene. 
Their data showed that elevated APP generation by increased message 
translation in response to IL-1 (Rogers et al., 1999). Based on the reports 
stated above, it is suggested that ATP-stimulated proinflmmatory cytokines 
could affect Aβ42 production by altering APP metabolism and activities of β- 
and γ-secretase enzymes. Hence, the possible underlying mechanism for the 




on proinflmmatory cytokines production, thereby decreasing the activities of 
secretases enzymes. 
After finding out that H2S inhibited Aβ42 production by altering 
activities of secretases, we sought to seek the underlying signaling mechanism. 
NF-κB regulates generation of many inflammatory mediators in immune cells.  
It is proposed that APP 5’ region contains transcription factor binding sites 
consensus sequence for NF-κB (Grilli et al., 1995), and so does the BACE1 
gene promoter (Bourne et al., 2007). Thus, it was reasonable to hypothesize 
that NF-κB may directly/indirectly regulate the process of amyloidogenesis. 
Indeed, Choi et al speculated that the NF-κB could be targeted for regulation 
of neuroinflammation and thus amyloidogenesis in AD. Many studies have 
reported that STATs have an influential role in Aβ production by affecting 
mechanisms of secretases. IFNγ-induced BACE1 expression has been shown 
to be regulated by JAK2 signaling pathway activation, an upstream pathway of 
STATs (Cho et al., 2007). Furthermore, it has been demonstrated that 
activated P2 receptors stimulate STAT3 activation and P2/STAT3 signaling 
can play an important role in neuroinflammation (Washburn and Neary, 2006). 
In the current study, effects of H2S on ATP-stimulated Aβ42 synthesis and 
activity of NF-κB in BV-2 microglial cells were nulled by STAT3 expression 
blockade with SC203282, the specific STAT3 inhibitor. These data indicate 
that inhibition of STAT3 by H2S inhibits severe inflammation as well as the 
resultant amyloidogenesis. Apparently, the phenomenon of STAT3-dependent 
NF-κB inactivation is a crucial target for H2S for its inhibitory effect on 




Aberrant lysosomal proteolytic system has been implicated in 
pathology of neurodegenerative diseases (Nakanishi, 2003b). Cathepsin S is a 
member of a large family of lysosomal cysteine proteases. They are expressed 
predominantly in the cells of mononuclear phagocytic origin (for example, 
microglia in CNS). It has a unique feature of being stable at neutral pH 
(Petanceska et al., 1996). As stated earlier, it has proven role in AD pathology. 
Cathepsin S splits APP at the β-secretase site (Schechter and Ziv, 2011). 
Munger et al noted the increased production of Aβ in HEK-293 cells 
transfected with cathepsin S (Munger et al., 1995). In an extensive study done 
by Liuzzo and colleagues, cathepsin S degrades monomeric and dimeric Aβ 
peptide at both acidic and neutral pH. Interestingly, they also observed the 
capability of cathepsin S to process human APP producing amyloidogenic 
fragments (Liuzzo et al., 1999). Aβ peptides are primarily ingested by 
microglia and degraded by its endosomal system (Nakanishi, 2003a). Thus, 
microglial cathepsin S can modulate the clearance of Aβ protecting neurons 
from toxic built-up of Aβ peptides (Pike et al., 1993). 
Nakamura and colleagues reported that concentration and localization 
of lysosomal cathepsins is altered in CNS of normal aged brains (Nakamura et 
al., 1989). Our results show that ATP treatment upped the expression and 
activity of cathepsin S, which were inhibited by NaHS pretreatment. 
Interestingly, we also found that blockade of STAT3 using specific STAT3 
inhibitor abolished expression and activity of cathepsin S, suggesting that 
cathepsin S probably lies downstream to STAT3. In our study, we came to the 
conclusion that NF-κB holds a key position in ATP-stimulated-




contribution of cathepsin S in the inhibitory effects of NaHS on NF-κB 
activity, as a specific cathepsin S inhibitor abolished DNA binding activity. 
Furthermore, ATP, NaHS and SC203282 failed to induce any significant 
effect on Aβ42 levels and NF-κB DNA binding activity in the presence of 
cathepsin S inhibitor.  These results suggest that H2S inhibits activity and 
expression of cathepsin S, thus downregulating its downstream pathway. 
One of the most important mechanisms associated with the 
physiological effects of H2S in various body systems is protein S-
sulfhydration. This post-translation modification controls the activity of many 
proteins by converting cysteine –SH (thiol) group to –SSH (persulfide) group 
(Mustafa et al., 2009). After the discovery of this phenomenon, at least 15 
proteins have been found to be modified via S-sulfhydration (Yang, 2014). In 
respect to the CNS, the S-sulfhydration of Parkin (Vandiver et al., 2013) and 
p66SHC (Xie et al., 2014) have been linked with their neuroprotective and 
anti-oxidative actions respectively. The study of protein structure of cysteine 
cathepsins has revealed the existence of conserved cysteine residue (Cys 25) 
in the active site cleft. Furthermore, Cys 25 has been observed to be located at 
N-terminus of central helix of L-domain. This cysteine residue is essential for 
the catalytic activity of cathepsin S (Turk et al., 2012). Therefore, we 
examined the S-sulfhydration of cathepsin S and found that it was 
significantly sulfhydrated at Cys-25 by the application of exogenous NaHS. In 
a comparison study, we induced mutation at Cys-216, which is believed to be 
involved in a disulfide bond formation in cathepsin S structure (Inagaki et al., 
2007). Our results showed that the mutation at this specific residue did not 




might inhibit cathepsin S by inducing conformational changes in protein 
structure. This may include altering hydrophobicity, electrostatic environment 
and proximity of target thiols to transition metals or redox centers (Zhao et al., 
2014a, Lu et al., 2013). However, it still requires further investigations to fully 
understand the changes in protein. 
In conclusion, we demonstrated for the first time that H2S inhibits 
neuroinflammation induced by extracellular ATP, which in turn suppresses Aβ 
production in BV-2 microglia cells. The mechanism for the observed effects of 
H2S involves inhibition of NF-κB, STAT3 and cathepsin S. We have also 
showed that H2S S-sulfhydrates cathepsin S to downregulate its activity. Our 
results imply that H2S can be potentially used for the treatment of AD with 


































Aβ deposition, chronic neuroinflammation and excitotoxicity have 
been identified as few key hallmark pathological features of AD. The 
pharmaceutical strategies targeting these pathological features have shown 
promising results on abolishing neurodegeneration. Several lines of 
investigations suggest that H2S produces anti-oxidative, anti-inflammatory and 
anti-apoptotic effects in various experimental models of neurodegerative 
diseases. In the current thesis, the emphasis has been put on anti-
amyloidogenic, anti-excitotoxic and anti-inflammatory properties of H2S  in 
various types of brain cells stimulated  by ATP metabolites.  
In the first part of the study, we found that NaHS, a fast exogenous 
H2S donor), suppressed HENECA (a selective A2A receptor agonist)-
stimulated Aβ42 synthesis in SH-SY5Y cells transfected with APP Swedish 
mutation. NaHS also interrupted HENECA-stimulated generation and post-
translational modification of APP by inhibiting its maturation process. 
Quantitative analysis of C-terminal APP fragments generated from its 
enzymatic splitting by BACE1 revealed that H2S did not affect β-secretase 
activity. On the other hand, the results from direct γ-secretase activity 
measurement and gene expression study of presenilins strongly indicated that 
the inhibition of Aβ42 generation by H2S was mediated by direct inhibition of 
γ-secretase.  Interestingly, NaHS also exerted similar suppressive effects on 
intracellular cAMP levels and phosphorylation of downstream CREB. NaHS 
notably abolished the stimulated cAMP and Aβ42 generation caused by AC 
activation. Additionally, NaHS pretreatment notably suppressed HENECA-
stimulated activity and gene expression of AC and its analogues. These data 




stimulated.  Conclusively, H2S suppressed HENECA stimulated Aβ42 
synthesis in SH-SY5Y cells by blocking γ-secretase through a cAMP 
dependent signaling pathway. 
In the second part of thesis, the effect of NaHS against glutamate 
neurotoxicity was tested in primary astrocytes. As it was evident from 
literature review, A2A adenosine receptors modulate glutamate uptake in glial 
cells. In this series of experiments, primary astrocytes were incubated with 
A2A adenosine receptor agonist, HENECA. It was found out that protein 
expression of GLAST glutamate transporter and glutamate uptake were 
significantly inhibited. The treatment with NaHS, however, repaired the 
glutamate uptake and expression of GLAST glutamate transporter. After 
confirming the restorative effect of NaHS, we proceeded to investigate the 
mechanisms involved. As A2A receptors are linked to AC, the increase in 
intracellular cAMP levels was observed when astrocytes were stimulated by 
HENECA. In the first part of the studies, we had noticed the inhibitory effect 
of NaHS on cAMP production in neuronal cells. We found the similar effects 
in primary astrocytes. Thus, it is highly probable that H2S-suppressed cAMP 
generation was probably responsible for its regenerative effect on glutamate 
uptake and restoration of GLAST. 
In the third part, the major aim of the study was to examine the 
potential therapeutic effects of H2S against neuroinflammation caused by 
extracellular ATP. Since the anti-inflammatory role of H2S in other body 
systems including cardiovascular and gastrointestinal systems has been 
examined previously by our and other groups, it was reasonable to speculate 




brain. In order to investigate this hypothesis, immortalized BV-2 microglia 
cells were used in the study to examine the effect of H2S treatment on 
extracellular ATP-induced severe neuroinflammation.  The concentrations of 
pro-inflammatory cytokines (i.e. TNF-α and IL-1β) in the culture supernatants 
were measured. The results indicated that H2S notably lowered ATP-
stimulated pro-inflammatory cytokines production in immortalized microglia. 
Moreover, the suppressing effect of H2S on ATP-induced oxidative stress (i.e. 
ROS and NO) was also observed in BV-2 cells. It was revealed that H2S, 
while exerting its anti-inflammatory effect, also imparted inhibitory effect on 
Aβ synthesis in microglia. Both the effects were achieved by blocking STAT3, 
cathepsin S and NF-κB activation.  
Collectively, we have demonstrated three possible mechanisms by 
which H2S can impart neuroprotective effects in AD disease model. Firstly, H 
H2S can directly reduce the amyloid burden by inhibiting Aβ production via a 
cAMP dependent pathway. Secondly, H2S could reduce the glutamate 
excitotoxicity by upregulating glutamate receptor expression and glutamate 
uptake, possibly via similar downstream mechanism as observed in SH-SY5Y 
cells. Lastly, H2S can suppress ATP-induced neuroinflammation and 
subsequent Aβ production by microglia. Scientific research of decades has 
demonstrated that multiple underlying mechanisms run parallel in the 
development of AD pathology. Aβ peptide are known to induce microglia 
mediated neuroinflammation and neurotoxicity. The damaged and thus 
defective clearance system results into accumulation of Aβ. Intracellular Aβ 
accumulation in turn upregulates a notable oxidative and inflammatory 




(Standridge, 2006). In our study, H2S may not only directly ameliorate 
neuroinflammation via STAT3 and Cathepsin S, but also indirectly by 
reducing synthesis and immunogenicity of Aβ in neurons and microglia 
However, this study on therapeutic potential of H2S against AD has 
some limitations. For starters, we studied the neuroprotective effects of NaHS, 
which is a rapid donor of H2S. NaHS quickly releases H2S when dissolved in 
water. Hence, it might not imitate physiological enzymatic production of H2S 
in mammalian cells. Furthermore, the neuroprotective effects of H2S were not 
re-tested in animal models of AD in this thesis. Although the established cell 
models used in out studies have their benefits, the transgenic animal models 
(e.g. APP/PS1 transgenic mouse model) are now a days increasingly used in 
evaluating therapeutic potentials of many compounds for AD therapy (Gotz et 
al., 2004). Since we have suggested the role of H2S as a potential therapeutic 
agent in treatment if AD, the potential difficulties of using a gaseous 
compound as a drug deserve a brief mention here. It's a fact that the 
therapeutic strategy of inhalation of H2S for its beneficial effects has not been 
evaluated widely. Firstly, the safety for inhaling H2S, which is known toxic 
agent, is and will always be an important issue (Wang, 2012). Keeping 
inhalational H2S in a therapeutic window is another concern. This is important 
because gaseous drugs (e.g. gaseous anesthetics) generally have a narrow 
therapeutic window, which has to be monitored with extreme care (Vlassakov 
and Kissin, 2014). However, these shortcomings can be overcome by the 
usage of H2S -releasing hybrid compounds. These compound are 
manufactured by combining H2S -releasing moiety and another compound 




diclofenac) have been demonstrated to have superior activity over NSAIDs or 
sulfur-containing molecules alone while acting against neuroinflammation. 
The data indicates that H2S -releasing hybrids possess notable anti-
inflammatory properties and can be potential drugs to treat AD that have 
prominent neuroinflammatory component (Lee et al., 2010, Sparatore et al., 
2011).  
Neuroprotective roles of H2S against AD pathology have been 
identified but nit yet completely elucidated. Further research efforts are in 
need in the following fields. 
• Identification of the role of endogenous H2S in the brain using 
popular genetic methodologies such as gene silencing or 
overexpression of CBS (mainly responsible for production of H2S 
in brain) 
• Establishment of specific pharmacological approaches to 
selectively inhibit H2S producing enzymes in the CNS 
• Identification of possible molecular target of H2S and elucidate the 
effects of H2S -mediated modifications (e.g. sulfhydration on the 
cysteine residue) on the adenosine A2A receptor signal 
transduction pathway. 
• Investigation of possible H2S -mediated sulfhydration on the Cys 
residues, which are engaged in the formation of disulfide bonds in 




At the end, we hope that active and diversified research in above 
mentioned directions would help address several unanswered questions about 
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